# Stem Cell Seoul > An educational reference on regenerative medicine in Korea: what stem-cell, exosome, PRP and polynucleotide treatments actually contain, what the published evidence does and does not support, and how Korean law regulates them. ## Regenerative medicine in Korea, explained from the evidence Source: https://stemcell-seoul.com/ Updated: 2026-10-18 ### Evidence register | Modality | Evidence level | Regulatory status | What to ask | | --- | --- | --- | --- | | [Autologous cells (MSC, SVF, ADSC)](https://stemcell-seoul.com/stem-cells-vs-exosomes/) | Systematic review of cell-assisted lipotransfer, where cells are added to a fat graft rather than injected as a treatment in themselves. Graft-retention rates in the underlying literature range from roughly 25% to 80%. Processing methods are not standardised between clinics. [What it is](https://stemcell-seoul.com/what-is-regenerative-medicine/) | US FDA approval for aesthetic indications: None for cosmetic use [Is it FDA approved?](https://stemcell-seoul.com/is-it-fda-approved/) [Korean law](https://stemcell-seoul.com/korea-regenerative-medicine-law/) | [Is this conducted as treatment or as clinical research, and under what authorisation?](https://stemcell-seoul.com/questions-to-ask-a-clinic/) | | [Exosomes / extracellular vesicles](https://stemcell-seoul.com/stem-cells-vs-exosomes/) | Small controlled trials and systematic reviews of extracellular vesicles and conditioned media; formulation and procedure differences limit generalisation. No exosome product holds US FDA approval for any indication. Isolation and characterisation methods differ between suppliers, so "exosome" on two labels need not mean the same material. [What it is](https://stemcell-seoul.com/what-is-regenerative-medicine/) | US FDA approval for aesthetic indications: None: no exosome product is approved for any indication [Is it FDA approved?](https://stemcell-seoul.com/is-it-fda-approved/) [Korean law](https://stemcell-seoul.com/korea-regenerative-medicine-law/) | [What exactly is being injected, and where did it come from?](https://stemcell-seoul.com/questions-to-ask-a-clinic/) | | [Platelet-rich plasma (PRP)](https://stemcell-seoul.com/prp-and-polynucleotides/) | Multiple systematic reviews and meta-analyses of randomised controlled trials, chiefly in androgenetic alopecia. A 2023 systematic review graded the certainty of benefit as low, citing inconsistency and risk of bias. Preparation protocols vary between studies. [What it is](https://stemcell-seoul.com/what-is-regenerative-medicine/) | [Is it FDA approved?](https://stemcell-seoul.com/is-it-fda-approved/) [Korean law](https://stemcell-seoul.com/korea-regenerative-medicine-law/) | [What is the strongest published evidence for this, in my indication?](https://stemcell-seoul.com/questions-to-ask-a-clinic/) | | [PDRN / polynucleotides (PN)](https://stemcell-seoul.com/prp-and-polynucleotides/) | A systematic review of nine studies in aesthetic use, plus a substantial pharmacology literature on PDRN in wound healing. The included aesthetic studies were of low to moderate quality, with 219 patients in total and no consensus on optimal use. [What it is](https://stemcell-seoul.com/what-is-regenerative-medicine/) | [Is it FDA approved?](https://stemcell-seoul.com/is-it-fda-approved/) [Korean law](https://stemcell-seoul.com/korea-regenerative-medicine-law/) | [What is the realistic range of outcomes, including no visible change?](https://stemcell-seoul.com/questions-to-ask-a-clinic/) | Korea regulates interventions within its statutory advanced regenerative medicine pathway through designated institutions and plan review. Specified minimally manipulated cell and tissue procedures are excluded from that pathway. Under one word, “regenerative”, sits a whole spectrum of products: living cells, platelet concentrates, cell-free vesicles, purified DNA fragments, each with its own evidence base. Parts of that spectrum are genuinely well studied: PRP for pattern hair loss has multiple meta-analyses of randomised trials, whose reviewers grade the certainty as low[3], while exosome products, for all their mechanistic promise, hold no United States FDA approval yet for any indication[1]. Figure: Four sample tubes containing red circles, layered amber liquid, blue dots and a dark strand ### Questions to ask a clinic in Seoul If you are considering a regenerative procedure in Seoul, use the [eight-question checklist](https://stemcell-seoul.com/questions-to-ask-a-clinic/) to ask about the product, evidence, risks and follow-up before agreeing. ### In short - Products marketed as "regenerative" range from living cells to purified salmon DNA. The differences are not cosmetic; they determine both the regulatory route and the evidence available. - No exosome product currently holds US FDA approval for any indication. When a page says "FDA approved", the useful follow-up is: which product, and in which record? - PRP for androgenetic alopecia has a comparatively larger randomised-trial evidence base: multiple meta-analyses of randomised trials report increased hair density, with the reviewers grading the certainty as low. - Interventions within Korea’s advanced regenerative medicine pathway require institutional designation and plan review. Statutory exclusions, institutional designation and product approval are separate questions. ### What the product contains Ask what is physically in the syringe. That single question sorts the field better than any brand name, because it predicts both what a regulator will call the product and what kind of study anyone has managed to run on it. Figure: Regenerative products differ in their contents. Product identity, processing and intended use determine the relevant regulatory pathway and clinical evidence. More cellular material None 1. Living nucleated cells - Autologous MSCs - Stromal vascular fraction - Adipose-derived cells 2. Anucleate fragments in plasma - Platelet-rich plasma (PRP) 3. Cell-derived preparations - Conditioned cell-culture medium - Exosomes and other extracellular vesicles 4. No cellular material - PDRN - Polynucleotides (PN) At one end sit preparations containing living nucleated cells: autologous mesenchymal stromal cells, stromal vascular fraction, adipose-derived cells. These are the products that the phrase “stem cell treatment” literally describes, and their regulatory status depends on processing and intended use. At the other end sit polynucleotides and PDRN: purified DNA fragments, in the case of PDRN derived from salmon sperm, containing no cellular material whatsoever[4]. In between are two categories that cause most of the confusion. Platelet-rich plasma is your own blood, spun down so that platelets are concentrated in a small volume of plasma: anucleate cell fragments, not stem cells. And exosomes are small vesicles released by cells, which are not living cells. The composition and purity of a preparation must be checked separately. That last category is the one where the vocabulary has run furthest ahead of the science; the International Society for Extracellular Vesicles has had to publish successive editions of minimum reporting standards partly because laboratories could not agree on what they were even measuring[5]. [The difference between stem cells and exosomes](https://stemcell-seoul.com/stem-cells-vs-exosomes/) is worth understanding before reading any clinic page on either. ### Clinical evidence and its limits Regenerative products have been studied in cell cultures, case series, controlled trials and systematic reviews. Exosome-containing preparations have small controlled studies and systematic reviews, but variations in formulation, combined procedures and short follow-up limit the conclusions[7, 8]. PRP for pattern hair loss has multiple meta-analyses of randomised trials. Cruciani and colleagues’ 2023 review included 18 androgenetic-alopecia trials with 713 participants and nine alopecia-areata trials with 404 participants; its certainty assessment found that evidence of benefit was limited and mostly low quality[3]. That is what a mature evidence base looks like in this field. Modalities with less research behind them are not better; they are just less examined. [How to read evidence levels in regenerative medicine](https://stemcell-seoul.com/evidence-levels/). ### The regulatory picture, in two jurisdictions US and Korean regulators determine status within their own jurisdictions. The United States FDA has published a standing consumer alert about regenerative medicine products including stem cells and exosomes, which is the document to read before weighing any claim about American approval status. Korea regulates advanced regenerative medicine through its own statute, which requires institutional designation and plan review for interventions within its defined scope and excludes specified minimally manipulated cell and tissue procedures. Neither fact tells you whether a particular clinic is operating properly. That is the part readers most often get wrong: a statute existing is not a clinic being licensed under it, and a paper being published is not a product being approved. Both [the Korean framework](https://stemcell-seoul.com/korea-regenerative-medicine-law/) and [the FDA-approval question](https://stemcell-seoul.com/is-it-fda-approved/) require separate records. ### Medical tourism raises the stakes A reader considering travelling for a regenerative procedure is taking on a risk profile that a local patient does not. A critical review of international stem cell tourism found that clinics offering these therapies are concentrated in jurisdictions with lighter oversight, that reported complications include infection, immune rejection and tumour formation, and that follow-up care after returning home is frequently nobody’s responsibility[6]. If you are reading this from outside Korea, the [safety page](https://stemcell-seoul.com/safety-and-risks/) and the [list of questions to ask a clinic](https://stemcell-seoul.com/questions-to-ask-a-clinic/) cover follow-up arrangements and the documents to obtain before travel. Directions and booking information for visitors from abroad are on [the international-patient page at Delight Dermatology](https://hifuseoul.com/for-international-patients/). Your skin and hair concerns need an individual assessment. ### References 1. Haykal D, Wyles S, Garibyan L, Cartier H, Gold M. Exosomes in Cosmetic Dermatology: A Review of Benefits and Challenges. *J Drugs Dermatol.* 2025;24(1):12-18. [doi:10.36849/JDD.8872](https://doi.org/10.36849/JDD.8872) · [PMID:39761139](https://pubmed.ncbi.nlm.nih.gov/39761139/) 2. Shah M, Dukharan V, Broughton L, et al. Exosomes for Aesthetic Dermatology: A Comprehensive Literature Review and Update. *J Cosmet Dermatol.* 2025;24(1):e16766. [doi:10.1111/jocd.16766](https://doi.org/10.1111/jocd.16766) · [PMID:39764639](https://pubmed.ncbi.nlm.nih.gov/39764639/) 3. Cruciani M, Masiello F, Pati I, Marano G, Pupella S, De Angelis V. Platelet-rich plasma for the treatment of alopecia: a systematic review and meta-analysis. *Blood Transfus.* 2023;21(1):24-36. [doi:10.2450/2021.0216-21](https://doi.org/10.2450/2021.0216-21) · [PMID:34967722](https://pubmed.ncbi.nlm.nih.gov/34967722/) 4. Lampridou S, Bassett S, Cavallini M, Christopoulos G. The Effectiveness of Polynucleotides in Esthetic Medicine: A Systematic Review. *J Cosmet Dermatol.* 2025;24(2):e16721. [doi:10.1111/jocd.16721](https://doi.org/10.1111/jocd.16721) · [PMID:39645667](https://pubmed.ncbi.nlm.nih.gov/39645667/) 5. Welsh JA, Goberdhan DCI, O'Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. *J Extracell Vesicles.* 2024;13(2):e12404. [doi:10.1002/jev2.12404](https://doi.org/10.1002/jev2.12404) · [PMID:38326288](https://pubmed.ncbi.nlm.nih.gov/38326288/) 6. Lyons S, Salgaonkar S, Flaherty GT. International stem cell tourism: a critical literature review and evidence-based recommendations. *Int Health.* 2022;14(2):132-141. [doi:10.1093/inthealth/ihab050](https://doi.org/10.1093/inthealth/ihab050) · [PMID:34415026](https://pubmed.ncbi.nlm.nih.gov/34415026/) 7. Park GH, Kwon HH, Seok J, et al. Efficacy of combined treatment with human adipose tissue stem cell-derived exosome-containing solution and microneedling for facial skin aging: A 12-week prospective, randomized, split-face study. *J Cosmet Dermatol.* 2023;22(12):3418-3426. [doi:10.1111/jocd.15872](https://doi.org/10.1111/jocd.15872) · [PMID:37377400](https://pubmed.ncbi.nlm.nih.gov/37377400/) 8. Jafarzadeh A, Hoseini SS, Behrangi E, Roohaninasab M, Goodarzi A. Effectiveness of regenerative medicine for skin lightening and rejuvenation: a systematic review of extracellular vesicles and conditioned media. *Stem Cell Res Ther.* 2025;16(1):513. [doi:10.1186/s13287-025-04592-z](https://doi.org/10.1186/s13287-025-04592-z) · [PMID:41013717](https://pubmed.ncbi.nlm.nih.gov/41013717/) ## Editorial policy, medical review and sources Source: https://stemcell-seoul.com/about-and-editorial-policy/ Updated: 2026-10-24 Medical review draws on cited clinical studies and official regulatory records. Figure: A funnel filtering colored circles, triangles and squares into a block ### Medical review Medical review: a Korean board-certified dermatologist. ### Regulatory scope FDA status is checked for the named stem-cell or exosome product and its indication. An approval for one disease does not establish approval for aesthetic use or authorisation to provide it in Korea. Ryoncil (remestemcel-L-rknd) is an FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease in pediatric patients 2 months of age and older. [FDA product record](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/ryoncil). The indication is disease-specific and does not include cosmetic use. ### Source selection Source selection prioritises systematic reviews, meta-analyses and controlled clinical trials. Laboratory findings and clinical outcomes are distinguished. References include PubMed identifiers and DOIs. ### Primary regulatory sources Regulatory sources are official agency records and legislation. Primary source [Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes): U.S. Food and Drug Administration Scope of this source: U.S. regulatory context only. Does not establish Korean legal status. Primary source [첨단재생의료 및 첨단바이오의약품 안전 및 지원에 관한 법률 (Act on the Safety of and Support for Advanced Regenerative Medicine and Advanced Biological Products)](https://law.go.kr/LSW/lsInfoP.do?ancYnChk=0&chrClsCd=010202&efYd=20261008&lsiSeq=285347&urlMode=lsInfoP): Korea Ministry of Government Legislation (국가법령정보센터) Scope of this source: In force: 8 October 2026; Act No. 21525, amended 7 April 2026. ### How claims are framed Clinical claims include the study design and certainty of evidence. Laboratory mechanisms and regulatory status are distinct from clinical benefit. ### Review and revision Medical review dates and editorial update dates are recorded separately. Review covers material changes in evidence or regulation and confirmed factual errors. ### Corrections Factual corrections are checked against supporting sources and reflected in the page revision date. Your skin and hair concerns need an individual assessment. ## Stem cell clinical trial registration vs approval Source: https://stemcell-seoul.com/clinical-trial-registration-vs-approval/ Updated: 2026-10-18 When a stem cell or exosome claim cites an NCT number, the number shows that a sponsor or investigator submitted a study record to ClinicalTrials.gov. It does **not** show that the intervention is approved, effective, suitable for a particular patient, authorised in Korea or lawfully available from a specific clinic. Figure: File folders and two vials stand beside a blank certificate with a green seal. ### What registration establishes [ClinicalTrials.gov](https://support.nlm.nih.gov/kbArticle/?pn=KA-03869) is a public registry and results database maintained by the US National Library of Medicine. Study information is supplied and updated by the sponsor or principal investigator. Registration makes a protocol record searchable and gives it a stable NCT identifier after submission and NLM quality-control review. That is useful. A record can show the study design, intervention, eligibility, outcome measures, sponsor, locations, recruitment status and whether summary results have been posted. It lets a reader compare what was planned with what was later reported. It should be read as a structured disclosure, not as a regulator's endorsement. [FDA consumer information on regenerative medicine therapies](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies) states that inclusion in ClinicalTrials.gov does not mean a product is lawfully marketed. That statement distinguishes registration from marketing status; it is not used here as a current exhaustive inventory of approved products. ### What NLM quality control does not establish A [2019 ClinicalTrials.gov procedural presentation](https://cdn.clinicaltrials.gov/documents/webinars/Webinar_Posting_Summary_Results_within_30_days.pdf) describes quality-control review as screening for apparent errors, deficiencies and inconsistencies. It does not verify the scientific validity or relevance of submitted information. Responsibility for the study and the accuracy of its record stays with the sponsor or investigator. The separation is especially clear in [NLM's guidance on ethics review](https://support.nlm.nih.gov/kbArticle/?pn=KA-03893): when a study requires review-board approval, it may still be registered before that approval if the status is *Not yet recruiting*. The record must be updated after approval and before recruiting begins. Registering a study and obtaining ethics approval are separate steps. | Signal | What it means | What it does not prove | | --- | --- | --- | | NCT number | The study has a public registry identifier | Product approval, efficacy or clinic permission | | Recruiting | The record says enrollment is open | That every reader is eligible or should enroll | | Completed | The study ended normally | A positive result or regulatory authorisation | | Results posted | Summary results are publicly available in the registry | Peer review, clinical importance or approval | ### How to check a clinical trial record 1. **Confirm the identifier.** Match the NCT number, study title and intervention. 2. **Read the study type and phase.** An observational record answers a different question from an interventional trial. 3. **Check the sponsor and responsible party.** They supply and maintain the record. 4. **Compare status dates.** First posted, last update and recruitment status describe different events. 5. **Look for posted results.** A registered protocol without results cannot establish the outcome. Check for any quality-control comments as well as the results themselves. 6. **Find the separate regulator record.** Approval or authorisation requires the relevant authority's product, indication and jurisdiction-specific documentation. ### Why a US registry record cannot prove Korean approval ClinicalTrials.gov is not a Korean product-authorisation database. A Korean claim needs the exact Korean record for the exact product, indication and regulatory path. The MFDS website is a starting point for checking regulator information, but its general landing page does not establish the status of a product, clinic or procedure. Device status works the same way: [Delight Dermatology’s model-by-model device records](https://hifuseoul.com/credentials/) keep FDA clearance and Korean authorisation as separate entries. If a page cites an NCT number as proof that a clinic may provide a stem-cell or exosome intervention, ask: Which Korean authority issued the relevant document? What document number, product or protocol, indication, institution and current status does it name? ### Frequently asked questions ### Does an NCT number mean a treatment is approved? No. An NCT number identifies a study record on ClinicalTrials.gov. It is not FDA approval, MFDS authorisation, proof that the intervention works, or permission for a clinic to provide it. ### Does ClinicalTrials.gov verify that a study is scientifically valid? No. NLM performs a limited quality-control review for apparent errors, deficiencies and inconsistencies. NLM states that its staff do not verify the scientific validity or relevance of submitted information. ### Can a study be registered before ethics approval? In some circumstances, yes. NLM says a study that requires human-subjects review may be registered before that approval if its status is Not yet recruiting. The record must be updated when approval is obtained before recruitment begins. ### Does a Completed status mean the treatment was successful? No. Completed describes study progress: the study ended normally and participants are no longer being examined or treated. It does not state whether the primary outcome was met or whether a regulator authorised the intervention. ### Can a US trial registration prove Korean approval? No. Korean product status and permission to conduct or provide a particular intervention require the relevant Korean documents. A ClinicalTrials.gov record cannot substitute for an MFDS or other applicable Korean authority record. ### Primary sources 1. National Library of Medicine. [What kind of website is ClinicalTrials.gov?](https://support.nlm.nih.gov/kbArticle/?pn=KA-03869) Registry ownership, submitted-information model and scope. 2. National Library of Medicine. [Can a study be entered before human-subjects review-board approval?](https://support.nlm.nih.gov/kbArticle/?pn=KA-03893) Registration and ethics-review timing. 3. [ClinicalTrials.gov glossary](https://clinicaltrials.gov/glossary). Definitions for registration, recruitment status and results records. 4. ClinicalTrials.gov. [Posting submitted summary results: quality-control review process](https://cdn.clinicaltrials.gov/documents/webinars/Webinar_Posting_Summary_Results_within_30_days.pdf). 2019 procedural presentation; apparent-problem screening and posting with comments. 5. US Food and Drug Administration. [Important patient and consumer information about regenerative medicine therapies](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies). Narrow source for registration versus lawful marketing status. 6. [식품의약품안전처 (Ministry of Food and Drug Safety)](https://www.mfds.go.kr/index.do). Korean regulator context; its existence does not establish any particular product or provider status. Related guides: [FDA approval language](https://stemcell-seoul.com/is-it-fda-approved/), [Korean regenerative-medicine law](https://stemcell-seoul.com/korea-regenerative-medicine-law/) and [how to compare evidence levels](https://stemcell-seoul.com/evidence-levels/). A registry record can help you ask better questions, but it cannot determine what is appropriate for you or establish that a specific intervention is authorised or offered. ## Evidence levels, and how to read them Source: https://stemcell-seoul.com/evidence-levels/ Updated: 2026-10-18 “Studies show” can mean a cell-culture experiment or a meta-analysis of randomised trials. PRP for pattern hair loss has multiple meta-analyses of randomised trials, with low certainty of benefit. Exosome-containing preparations also have small controlled studies and systematic reviews, with substantial limitations. Study design, sample size and product identity all affect how far a result can be applied.[9, 10] Figure: Descending bars in blue, red, yellow and white outlines ### The ladder, and who is standing on which rung Figure: Study design and certainty are separate: a systematic review can still find low-certainty evidence. 1. Systematic reviews and meta-analyses Tier 1 PRP: randomised-trial meta-analyses with low certainty. Polynucleotides and extracellular-vesicle/conditioned-media preparations: reviews of small, varied studies. 2. Controlled clinical trials Tier 2 PRP trials and small trials of exosome-containing preparations, including combined procedures. 3. Uncontrolled studies and case reports Tier 3 Early clinical observations cannot separate treatment effects from other changes. 4. Mechanism, cell culture and animal models Tier 4 Biological mechanisms can support research hypotheses but do not establish clinical benefit. Study quality, sample size and follow-up matter at every level. Each tier answers a different question. Mechanism and cell-culture work answer “could this plausibly do something?” Case series answer “did something happen when we tried it?” Randomised controlled trials answer “did it happen because of the treatment rather than time, placebo, or selection?” Systematic reviews and meta-analyses assess how consistent the findings are across studies. Marketing copy routinely borrows the language of the top tier to describe findings from the bottom one. A phrase like “clinically proven to stimulate collagen” is compatible with a fibroblast culture experiment. It is worth training yourself to notice which question a cited study was built to answer. ### The case study: PRP for pattern hair loss PRP for androgenetic alopecia has randomised controlled trials and multiple independent meta-analyses. Cruciani and colleagues’ 2023 review included 27 controlled alopecia trials: 18 androgenetic-alopecia trials with 713 participants and nine alopecia-areata trials with 404 participants. A smaller subset of androgenetic-alopecia trials contributed to the pooled comparison against saline; its certainty was rated low under GRADE because of inconsistency and risk of bias[1]. A separate meta-analysis restricted to nine randomised controlled trials in 238 patients found increased hair density at three and six months against placebo, while hair count and hair diameter improved from baseline without reaching significance against placebo[2]. A third, restricted to female pattern hair loss across seven studies, found increased terminal hair density but not thickness, and its authors explicitly recommended caution until the finding is replicated in larger and more representative samples[3]. Read together those three tell a consistent story: [a real but modest signal on one outcome](https://hifuseoul.com/procedures/prp-seoul/), inconsistent effects on others, and reviewers who decline to overstate it. That is what honest evidence looks like when it is neither nothing nor proof. ### How to read a systematic review in one minute - Find the certainty rating. GRADE terms (high, moderate, low, very low) appear in the abstract of a well-conducted review. "Low" is a finding, not a footnote. - Count the patients, not the studies. Nine studies covering 219 people is a small evidence base described in a way that sounds larger. - Check whether the comparison is against placebo or against baseline. Improvement from baseline includes everything that would have happened anyway. - Look for what the reviewers say they could not pool. Heterogeneous protocols usually mean the studies were not testing quite the same thing. - Note the follow-up period. A result at six months says nothing about two years. ### Where the other modalities sit Polynucleotides have one systematic review in aesthetic medicine: nine studies, 219 patients, rated low to moderate quality, with promising results on wrinkle depth, texture and elasticity and no consensus on optimal use[4]. Study quality, sample size and consistency matter alongside the review design. Exosome-containing preparations have small controlled studies, including a 28-person randomised split-face study combined with microneedling. A 2025 systematic review assessed extracellular vesicles and conditioned media for skin rejuvenation. These studies differ in product composition and delivery, and combined procedures and short follow-up limit conclusions about a specific product used alone[9, 10]. A parallel review is more direct: no FDA-approved exosome products exist, isolation methods are inconsistent, source material varies, and clinical trials establishing long-term safety and efficacy have yet to be done[6]. The measurement problem underneath all of it is why the field publishes and revises minimum reporting standards[8]. Live-cell aesthetic applications are the hardest to summarise because the clinical literature largely concerns cells as an adjunct to fat grafting rather than as a standalone treatment, and even there the systematic review reports retention rates spanning 25 to 80 per cent and unresolved manufacturing questions[7]. ### Three phrases that should slow you down **“Clinically proven.”** Not a defined term. Ask which trial, in how many people, against what comparator, measuring what. **“Studies show it stimulates collagen.”** Usually true and usually about cells in a dish. Whether it visibly changes a face is a different study. **“Patients report high satisfaction.”** Satisfaction is worth measuring and is not an outcome measure of biological effect. Uncontrolled satisfaction data cannot separate treatment from expectation. Evidence levels answer whether a treatment works on average. Whether it is the right choice for you depends on your diagnosis, and for hair and skin concerns the diagnosis is frequently the part that has been skipped. ### References 1. Cruciani M, Masiello F, Pati I, Marano G, Pupella S, De Angelis V. Platelet-rich plasma for the treatment of alopecia: a systematic review and meta-analysis. *Blood Transfus.* 2023;21(1):24-36. [doi:10.2450/2021.0216-21](https://doi.org/10.2450/2021.0216-21) · [PMID:34967722](https://pubmed.ncbi.nlm.nih.gov/34967722/) 2. Zhang X, Ji Y, Zhou M, et al. Platelet-Rich Plasma for Androgenetic Alopecia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *J Cutan Med Surg.* 2023;27(5):504-508. [doi:10.1177/12034754231191461](https://doi.org/10.1177/12034754231191461) · [PMID:37533146](https://pubmed.ncbi.nlm.nih.gov/37533146/) 3. de Oliveira AFQ, Arcanjo FPN, Rodrigues MRP, Rosa e Silva AA, Hall PR. Use of autologous platelet-rich plasma in androgenetic alopecia in women: a systematic review and meta-analysis. *J Dermatolog Treat.* 2023;34(1):2138692. [doi:10.1080/09546634.2022.2138692](https://doi.org/10.1080/09546634.2022.2138692) · [PMID:36264022](https://pubmed.ncbi.nlm.nih.gov/36264022/) 4. Lampridou S, Bassett S, Cavallini M, Christopoulos G. The Effectiveness of Polynucleotides in Esthetic Medicine: A Systematic Review. *J Cosmet Dermatol.* 2025;24(2):e16721. [doi:10.1111/jocd.16721](https://doi.org/10.1111/jocd.16721) · [PMID:39645667](https://pubmed.ncbi.nlm.nih.gov/39645667/) 5. Shah M, Dukharan V, Broughton L, et al. Exosomes for Aesthetic Dermatology: A Comprehensive Literature Review and Update. *J Cosmet Dermatol.* 2025;24(1):e16766. [doi:10.1111/jocd.16766](https://doi.org/10.1111/jocd.16766) · [PMID:39764639](https://pubmed.ncbi.nlm.nih.gov/39764639/) 6. Haykal D, Wyles S, Garibyan L, Cartier H, Gold M. Exosomes in Cosmetic Dermatology: A Review of Benefits and Challenges. *J Drugs Dermatol.* 2025;24(1):12-18. [doi:10.36849/JDD.8872](https://doi.org/10.36849/JDD.8872) · [PMID:39761139](https://pubmed.ncbi.nlm.nih.gov/39761139/) 7. Debuc B, Gendron N, Cras A, et al. Improving Autologous Fat Grafting in Regenerative Surgery through Stem Cell-Assisted Lipotransfer. *Stem Cell Rev Rep.* 2023;19(6):1726-1754. [doi:10.1007/s12015-023-10568-4](https://doi.org/10.1007/s12015-023-10568-4) · [PMID:37261667](https://pubmed.ncbi.nlm.nih.gov/37261667/) 8. Welsh JA, Goberdhan DCI, O'Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. *J Extracell Vesicles.* 2024;13(2):e12404. [doi:10.1002/jev2.12404](https://doi.org/10.1002/jev2.12404) · [PMID:38326288](https://pubmed.ncbi.nlm.nih.gov/38326288/) 9. Park GH, Kwon HH, Seok J, et al. Efficacy of combined treatment with human adipose tissue stem cell-derived exosome-containing solution and microneedling for facial skin aging: A 12-week prospective, randomized, split-face study. *J Cosmet Dermatol.* 2023;22(12):3418-3426. [doi:10.1111/jocd.15872](https://doi.org/10.1111/jocd.15872) · [PMID:37377400](https://pubmed.ncbi.nlm.nih.gov/37377400/) 10. Jafarzadeh A, Hoseini SS, Behrangi E, Roohaninasab M, Goodarzi A. Effectiveness of regenerative medicine for skin lightening and rejuvenation: a systematic review of extracellular vesicles and conditioned media. *Stem Cell Res Ther.* 2025;16(1):513. [doi:10.1186/s13287-025-04592-z](https://doi.org/10.1186/s13287-025-04592-z) · [PMID:41013717](https://pubmed.ncbi.nlm.nih.gov/41013717/) ## Before accepting an exosome product claim: five records to ask for Source: https://stemcell-seoul.com/exosome-product-evidence-checklist/ Updated: 2026-10-18 An “exosome” label does not identify the material in a particular container. Start with the exact product and lot, then ask for records that connect the claim to that material. Figure: Editorial illustration of a folder with five document tabs, a magnifying glass and abstract extracellular-vesicle-like circles ### Why one label is not enough Extracellular vesicles are heterogeneous. The [MISEV2023 consensus guidance](https://pmc.ncbi.nlm.nih.gov/articles/PMC10850029/) asks researchers to report source and pre-analytical variables, separation and concentration methods, and complementary characterization. The guidance supports transparent reporting; it does not certify a commercial product or establish a treatment benefit. That distinction changes the question. Instead of asking whether a brochure “mentions exosomes,” ask whether the documents follow the exact material from source through processing, characterization and the lot being discussed. The same product-first approach runs through [a skin-booster guide built around product identity](https://hifuseoul.com/procedures/skin-booster-seoul/). Figure: Five-step diagram linking product identity to processing, characterization, a lot-specific report and regulatory or research records The record chain should stay attached to the same product and lot. ### Product identity and source Ask for the product name, manufacturer and the tissue or cell source. For cultured material, ask which cells and culture conditions were used. MISEV2023 explains that source, culture conditions and other pre-analytical variables affect how an extracellular-vesicle preparation can be interpreted. A generic ingredient name cannot connect a claim to the material you are being shown. Record the exact product and lot before comparing any other document. ### Processing and storage Ask how the material was collected, separated, concentrated and stored, including temperatures and freeze-thaw history. A kit name alone does not describe the whole process. MISEV2023 calls for enough methodological detail to interpret and reproduce a preparation. ### Characterization Look for complementary measurements of the preparation, such as particle size and abundance, vesicle-associated components and co-isolated material. A single marker or a large particle count does not answer all of those questions. MISEV2023 discusses the limits of individual methods and recommends reporting several kinds of evidence together. ### A report linked to the lot Check whether the report identifies the lot being discussed and states what was measured, when, by whom and under which storage conditions. A report for another lot does not establish those results for this one. The [ISEV position paper on clinical translation of extracellular vesicles](https://pmc.ncbi.nlm.nih.gov/articles/PMC4698466/) discusses batch reproducibility and predefined, product-specific release criteria for investigational extracellular-vesicle products. Applying that principle here is a document-review question, not a claim that every consumer is entitled to a particular certificate. ### Regulatory or research pathway records The [FDA public safety alert](https://www.fda.gov/safety/medical-product-safety-information/public-safety-alert-due-marketing-unapproved-stem-cell-and-exosome-products), rechecked on 7 October 2026, states that there are currently no FDA-approved exosome products. FDA’s separate [regenerative-medicine consumer information](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies) explains that investigational use in the United States follows an IND pathway. A company registration or study listing is not product approval, and a research record does not prove benefit. Those are United States sources. They do not establish Korean status. For a claim about Korea, ask for the exact Korean document, authority, product or protocol, indication and current status. The [MFDS site](https://www.mfds.go.kr/index.do) is a regulator starting point; its general landing page does not verify a particular product or provider. ### What the paperwork can and cannot establish | The records can help you check | The records do not by themselves prove | | --- | --- | | Which product and lot a claim refers to | That the claimed clinical effect occurred | | Which methods and measurements were reported | That the methods are sufficient for every purpose | | Which jurisdiction and research pathway a document belongs to | Approval, Korean status or permission for a specific clinic | Missing paperwork alone does not establish that a product is unlawful. A complete folder also does not establish that a treatment is effective. MISEV2023 is scientific reporting guidance, not a product approval system. ### Primary sources 1. Welsh et al. [Minimal information for studies of extracellular vesicles (MISEV2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10850029/). Source, pre-processing, separation and characterization guidance. 2. Lener et al. [Applying extracellular vesicles based therapeutics in clinical trials](https://pmc.ncbi.nlm.nih.gov/articles/PMC4698466/). ISEV position paper on manufacturing, reproducibility and release criteria for investigational products. 3. US Food and Drug Administration. [Public safety alert on unapproved stem-cell and exosome products](https://www.fda.gov/safety/medical-product-safety-information/public-safety-alert-due-marketing-unapproved-stem-cell-and-exosome-products). United States status statement; rechecked 7 October 2026. 4. US Food and Drug Administration. [Important patient and consumer information about regenerative medicine therapies](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies). United States investigational-use context; content-current marker 8 April 2024, rechecked 7 October 2026. 5. Republic of Korea, Ministry of Food and Drug Safety. [MFDS official site](https://www.mfds.go.kr/index.do). Korean regulator starting point; it does not establish the status of a particular product, provider or protocol. Related guides: [stem cells versus exosomes](https://stemcell-seoul.com/stem-cells-vs-exosomes/), [FDA approval language](https://stemcell-seoul.com/is-it-fda-approved/) and [clinical trial registration versus approval](https://stemcell-seoul.com/clinical-trial-registration-vs-approval/). Documents can make a claim easier to examine. They cannot determine personal suitability or establish that a particular intervention is authorised, offered or effective. ## Frequently asked questions Source: https://stemcell-seoul.com/faq/ Updated: 2026-10-18 Stem cells are living cells; exosomes are extracellular vesicles; PRP contains concentrated platelets. Evidence and regulatory requirements differ by product and use. Figure: A stack of blue-edged cards with a red two-way arrow ### Is stem cell or exosome treatment FDA approved? No. No exosome product holds United States FDA approval for any indication[1], and no stem-cell product is FDA approved for a cosmetic indication. It is also worth separating two questions that get merged: US approval status does not determine legality in Korea, which regulates advanced regenerative medicine under its own statute. [The full answer, including what “cleared” means](https://stemcell-seoul.com/is-it-fda-approved/). ### What is the difference between stem cells and exosomes? A stem cell is a living cell that can divide. An exosome is a nanoscale vesicle released by a cell (roughly 30 to 150 nanometres) carrying protein, lipid and nucleic acid cargo[1]. Exosomes are produced by cells but are not cells: exosomes do not self-replicate or engraft as living cells; their tissue residence and clearance depend on the preparation and delivery route, and the proposed mechanism is signalling rather than tissue replacement. A practical complication is that exosome isolation methods differ between suppliers, which is why the research community publishes and revises minimum reporting standards[8]. [Side-by-side comparison](https://stemcell-seoul.com/stem-cells-vs-exosomes/). ### Is PRP a stem cell treatment? No. Platelet-rich plasma is the patient’s own blood, centrifuged so platelets concentrate into a small plasma volume. Platelets are anucleate cell fragments (not stem cells), and PRP contains none. [What PRP actually is](https://stemcell-seoul.com/prp-and-polynucleotides/). ### Does PRP work for hair loss? Partly, and the honest summary is modest. Multiple independent meta-analyses of randomised trials in androgenetic alopecia find increased hair density against placebo[2, 3]. Cruciani and colleagues’ 2023 review included 27 controlled alopecia trials: 18 androgenetic-alopecia trials with 713 participants and nine alopecia-areata trials with 404 participants. The pooled hair-density comparison against saline used a smaller subset of the androgenetic-alopecia trials, and its certainty was rated low under GRADE because of inconsistency and risk of bias[2]. Effects on hair count and diameter were less consistent than on density. FDA-approved medicines include topical minoxidil and oral finasteride for their labelled populations; certain low-level light devices are FDA-cleared for specified pattern-hair-loss indications[7], and a discussion that reaches PRP without addressing them has skipped a step. ### Can I legally receive stem cell treatment in Korea? Korea regulates advanced regenerative medicine under a dedicated statute that requires designation and plan review for interventions within its advanced regenerative medicine pathway, and distinguishes clinical research from treatment. Specified minimally manipulated cell and tissue procedures are excluded from that pathway. Whether a particular intervention at a particular clinic is authorised is a documentary question to put to that clinic: the framework existing does not answer it. [How the framework works](https://stemcell-seoul.com/korea-regenerative-medicine-law/). ### Are exosome facials worth it? The evidence does not currently support a confident answer either way. A 2025 comprehensive review found early evidence supporting exosome use for alopecia, facial rejuvenation, hyperpigmentation and scarring, drawn largely from small studies and case reports, while identifying the absence of standardisation in production and application as limiting current use[5]. No exosome product has US FDA approval[1]. Product-specific evidence and regulatory records are both needed. ### How much does regenerative treatment cost in Seoul? Ask the clinic for a written quote after an examination. It should identify the product, method, total cost and follow-up care. Comparing clinics on price alone is a separate question, covered in [a note on price-led clinic choices](https://hifuseoul.com/blog/hidden-cost-cheap-dermatology-clinics/). ### Is it safe? It depends on which modality, prepared how, under what oversight. In the pooled PRP trials no serious adverse events were reported, but incomplete reporting and limited follow-up prevent reliable estimates of uncommon harms[2], and the systematic review of polynucleotides in aesthetic medicine described side effects as generally mild and transient[4]. For unproven cell-based interventions offered outside research frameworks, the critical review literature documents infection, immune rejection and tumour formation[6]. [The full safety picture](https://stemcell-seoul.com/safety-and-risks/). ### What should I ask a clinic before agreeing? Eight questions, starting with what exactly is being injected and where it came from, and ending with who manages a complication after you fly home. [The checklist](https://stemcell-seoul.com/questions-to-ask-a-clinic/) gives each question with what a substantive and an evasive answer sound like. Bring your diagnosis and current treatment list to the consultation. ### References 1. Haykal D, Wyles S, Garibyan L, Cartier H, Gold M. Exosomes in Cosmetic Dermatology: A Review of Benefits and Challenges. *J Drugs Dermatol.* 2025;24(1):12-18. [doi:10.36849/JDD.8872](https://doi.org/10.36849/JDD.8872) · [PMID:39761139](https://pubmed.ncbi.nlm.nih.gov/39761139/) 2. Cruciani M, Masiello F, Pati I, Marano G, Pupella S, De Angelis V. Platelet-rich plasma for the treatment of alopecia: a systematic review and meta-analysis. *Blood Transfus.* 2023;21(1):24-36. [doi:10.2450/2021.0216-21](https://doi.org/10.2450/2021.0216-21) · [PMID:34967722](https://pubmed.ncbi.nlm.nih.gov/34967722/) 3. Zhang X, Ji Y, Zhou M, et al. Platelet-Rich Plasma for Androgenetic Alopecia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *J Cutan Med Surg.* 2023;27(5):504-508. [doi:10.1177/12034754231191461](https://doi.org/10.1177/12034754231191461) · [PMID:37533146](https://pubmed.ncbi.nlm.nih.gov/37533146/) 4. Lampridou S, Bassett S, Cavallini M, Christopoulos G. The Effectiveness of Polynucleotides in Esthetic Medicine: A Systematic Review. *J Cosmet Dermatol.* 2025;24(2):e16721. [doi:10.1111/jocd.16721](https://doi.org/10.1111/jocd.16721) · [PMID:39645667](https://pubmed.ncbi.nlm.nih.gov/39645667/) 5. Shah M, Dukharan V, Broughton L, et al. Exosomes for Aesthetic Dermatology: A Comprehensive Literature Review and Update. *J Cosmet Dermatol.* 2025;24(1):e16766. [doi:10.1111/jocd.16766](https://doi.org/10.1111/jocd.16766) · [PMID:39764639](https://pubmed.ncbi.nlm.nih.gov/39764639/) 6. Lyons S, Salgaonkar S, Flaherty GT. International stem cell tourism: a critical literature review and evidence-based recommendations. *Int Health.* 2022;14(2):132-141. [doi:10.1093/inthealth/ihab050](https://doi.org/10.1093/inthealth/ihab050) · [PMID:34415026](https://pubmed.ncbi.nlm.nih.gov/34415026/) 7. Nestor MS, Ablon G, Gade A, Han H, Fischer DL. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. *J Cosmet Dermatol.* 2021;20(12):3759-3781. [doi:10.1111/jocd.14537](https://doi.org/10.1111/jocd.14537) · [PMID:34741573](https://pubmed.ncbi.nlm.nih.gov/34741573/) 8. Welsh JA, Goberdhan DCI, O'Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. *J Extracell Vesicles.* 2024;13(2):e12404. [doi:10.1002/jev2.12404](https://doi.org/10.1002/jev2.12404) · [PMID:38326288](https://pubmed.ncbi.nlm.nih.gov/38326288/) ## “FDA registered” is not “FDA approved”: how to read FDA records on stem cell and exosome products Source: https://stemcell-seoul.com/fda-registered-vs-approved-records/ Updated: 2026-10-17 An “FDA-registered” or “FDA-listed” claim needs an identifiable record. For HCT/P registration and listing under 21 CFR Part 1271, FDA’s acceptance of the filing is **not** a determination of compliance, licensure or approval. A biologics licence is a separate record for a named product and a stated indication. Figure: Painted illustration of a quiet records room with shelves of plain archive boxes and folders in daylight ### HCT/P registration and listing under 21 CFR Part 1271 [21 CFR Part 1271](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271) covers human cells, tissues, and cellular and tissue-based products (HCT/Ps). Establishments whose HCT/Ps are regulated solely under section 361 of the Public Health Service Act register and list them under Part 1271; HCT/Ps regulated as drugs, devices or biological products follow other registration routes (§ 1271.1(b)). The listing must state whether each HCT/P meets the criteria in § 1271.10. Figure: Painted illustration of a wooden card catalogue with one drawer open and blank index cards inside A listing records what the establishment says it makes. The regulation is explicit about what FDA’s acceptance means: “FDA acceptance of an establishment registration and HCT/P listing form does not constitute a determination that an establishment is in compliance with applicable rules and regulations or that the HCT/P is licensed or approved by FDA” (§ 1271.27(b)). FDA’s [public query page](https://www.fda.gov/vaccines-blood-biologics/biologics-establishment-registration/human-cell-and-tissue-establishment-registration-hcters-public-query-application) adds a third limit: the filing also does not establish “that the HCT/P is appropriately regulated solely under section 361 of the PHS Act.” FDA’s [consumer information on regenerative medicine therapies](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies) adds that the fact a firm “has registered with FDA and listed its product does not mean the product is legally marketed.” ### Seven FDA records and what each one shows #### Establishment registration - **Who creates it:** The establishment, electronically (§ 1271.22). Each registered location receives a registration number (§ 1271.27(a)), and registration is updated each December (§ 1271.21(b)). - **What it shows:** That the establishment filed its legal name, locations and reporting official with FDA’s Center for Biologics Evaluation and Research, and the status shown in the public query. - **What it does not show:** Compliance with the rules, a licence or an approval (§ 1271.27(b)). - **How to check:** Search the [Human Cell and Tissue Establishment Registration public query](https://www.fda.gov/vaccines-blood-biologics/biologics-establishment-registration/human-cell-and-tissue-establishment-registration-hcters-public-query-application) by establishment name, function, product, status or location. Status can be registered, inactive or pre-registered; note which one applies and match the legal name and location to the claim. #### HCT/P listing - **Who creates it:** The same establishment, as part of its registration (§ 1271.25(b)). - **What it shows:** Which HCT/Ps the establishment says it handles, and whether it states that each one meets the § 1271.10 criteria, such as minimal manipulation and homologous use. - **What it does not show:** That FDA agrees with that statement. An HCT/P that does not meet the criteria, and qualifies for no exception, is regulated as a drug, device and/or biological product (§ 1271.20). - **How to check:** The same public query, searched by product. #### Investigational New Drug application (IND) - **Who creates it:** A clinical study sponsor. FDA’s [IND page](https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/investigational-new-drug-applications-inds-cber-regulated-products) describes it as “a request from a clinical study sponsor to obtain authorization from the Food and Drug Administration (FDA) to administer an investigational drug or biological product to humans.” - **What it shows:** That a sponsor has sought FDA authorisation to use an investigational product in a study. - **What it does not show:** A licence to market the product. FDA’s [BLA page](https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/biologics-license-applications-blas-cber-regulated-products) describes IND-stage studies as collecting safety and efficacy information for a later licence application. - **How to check:** FDA’s [2019 notification on exosome products](https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-products) suggests asking the clinical investigator for the FDA-issued IND number and the FDA communication acknowledging the IND before treatment. Under [21 CFR 312.40(b)](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-C/section-312.40), FDA notifies the sponsor of the date it received an IND and the IND takes effect later, so acknowledgment of receipt alone does not establish permission to proceed; ask for the relevant FDA correspondence. An NCT number is a separate registry identifier: see [clinical trial registration versus approval](https://stemcell-seoul.com/clinical-trial-registration-vs-approval/). #### Biologics licence (BLA approval) - **Who creates it:** The applicant, through a Biologics License Application: in FDA’s words, the submission “through which an applicant requests permission to introduce a biological product into interstate commerce.” - **What it shows:** If FDA finds that the data adequately demonstrate the product’s safety, effectiveness and quality, and that the facility meets the required standards, it issues a US licence to market that product. The licence belongs to a named product, manufacturer and indication. - **What it does not show:** Anything about a different product, even one made from a similar kind of cell, or about a use outside the licensed indication. - **How to check:** The product page reached from FDA’s approved-products list, described next. #### The approved cellular and gene therapy products list - **Who creates it:** FDA. The [list](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products) introduces itself as “a list of licensed products from the Office of Therapeutic Products (OTP).” On 17 October 2026 it carried a content-current date of 17 September 2026. - **What it shows:** Each licensed product by trade name and proper name, with its manufacturer and a link to a product page. The RYONCIL page, for example, states the indication and links the approval documents. - **What it does not show:** A register of every product FDA regulates. Absence from this list is not a finding about a product. - **How to check:** Find the exact trade and proper name, open the product page, and compare its indication with the claim. #### Warning letters - **Who creates it:** FDA. Its [explanation of warning letters](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/about-warning-and-close-out-letters) says: “When FDA identifies what it believes are significant violation(s) of federal requirement(s), FDA notifies the appropriate party. This notification is often in the form of a Warning Letter.” - **What it shows:** The concerns FDA stated, to whom and on what date. The letter asks for a response, and the recipient may address the concerns or supply its own reasoning. - **What it does not show:** Current compliance by itself; subsequent FDA correspondence may change the status of the issues. FDA may issue a close-out letter after it has verified corrective actions, usually by a follow-up inspection. - **How to check:** Enter the company name from the claim in FDA’s [warning-letter search](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters). Results show the posted and issue dates, issuing office and subject, and can be filtered for response or close-out letters. Read the letter itself: the body describes the products and claims at issue. #### Consumer alerts and safety notifications - **Who creates it:** FDA, for the public. - **What it shows:** FDA’s view on the date of the page. The [2019 Public Safety Notification on Exosome Products](https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-products) states: “There are currently no FDA-approved exosome products.” It also states that, as a general matter, exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products subject to premarket review and approval requirements. The [consumer alert on regenerative medicine products](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes) repeats the exosome statement. - **What it does not show:** The status of a particular product or firm, or anything that changed after the page date. - **How to check:** Compare the page’s “Content current as of” date with the current product record. ### Reading a product licence: a named product and a stated indication FDA’s [RYONCIL product page](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/ryoncil) lists the product’s STN (125706), its proper name, the manufacturer, the indication and an approval letter dated 19 December 2024. Ryoncil (remestemcel-L-rknd) is an FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease in pediatric patients 2 months of age and older. That record does not extend to another mesenchymal stromal cell preparation, to a cosmetic use, or to any status in Korea. Dated summaries can lag: the consumer alert, current as of April 2024, predates that approval letter. ### How to check an FDA claim Figure: Painted illustration of a magnifying glass resting on a stack of blank documents beside a desk lamp Check the record itself, not a summary of it. 1. **Copy the exact wording.** “Registered,” “listed,” “investigational,” “licensed” and “approved” point to different records. 2. **Identify the subject.** Note the legal name, location and exact product name. 3. **Open the matching record.** Use the public query for registration and listing, the IND number and relevant FDA correspondence for a study, the approved-products list and product page for a licence, and the warning-letter search for compliance correspondence. 4. **Read the dates and status.** Note the registration status, each page’s “Content current as of” date, letter issue dates, and any response or close-out letter. 5. **Keep the jurisdiction separate.** These are United States records. FDA’s exosome notification states that FDA “does not have oversight of treatments done in other countries.” A claim about Korea needs Korean records; the [guide to Korean regenerative-medicine law](https://stemcell-seoul.com/korea-regenerative-medicine-law/) explains which ones. For the status question itself, see [whether stem cell or exosome treatment is FDA approved](https://stemcell-seoul.com/is-it-fda-approved/). Device claims are checked the same way, model by model, as in [a clinic’s published record list](https://hifuseoul.com/credentials/). ### Frequently asked questions ### Does “FDA registered” mean a stem cell product is approved? No. Under 21 CFR 1271.27(b), FDA acceptance of an HCT/P registration and listing is not a determination of compliance, licensure or approval. ### What does an FDA warning letter about an exosome or stem cell product establish? It records the concerns FDA stated to a named recipient on a given date and asks for a response. Finding no letter does not establish compliance. ### Does an FDA registration say anything about a clinic in Korea? Not about treatment in Korea. Foreign HCT/P establishments may have US registration obligations, depending on their activities and applicable exceptions. ### Primary sources 1. [21 CFR Part 1271: Human cells, tissues, and cellular and tissue-based products (eCFR)](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271). Registration, listing, § 1271.10 criteria and § 1271.27(b); eCFR current to 15 October 2026. 2. [FDA: Human Cell and Tissue Establishment Registration (HCTERS) public query application](https://www.fda.gov/vaccines-blood-biologics/biologics-establishment-registration/human-cell-and-tissue-establishment-registration-hcters-public-query-application). Limits of registration and listing; query options. 3. [FDA: Important patient and consumer information about regenerative medicine therapies](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies). Registration and listing in marketing; current as of 8 April 2024. 4. [21 CFR 312.40: General requirements for use of an investigational new drug (eCFR)](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-C/section-312.40). Receipt notice and IND effective date. 5. [FDA: Investigational New Drug applications (INDs) for CBER-regulated products](https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/investigational-new-drug-applications-inds-cber-regulated-products). Definition of an IND. 6. [FDA: Biologics License Applications (BLAs) for CBER-regulated products](https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/biologics-license-applications-blas-cber-regulated-products). Definition of a BLA and when a licence issues. 7. [FDA: Approved cellular and gene therapy products](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products). Licensed OTP products; current as of 17 September 2026. 8. [FDA: RYONCIL (remestemcel-L-rknd) product page](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/ryoncil). One product and one indication. 9. [FDA: Warning letters search](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters). Record type and search fields. 10. [FDA: About warning and close-out letters](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/about-warning-and-close-out-letters). Warning and close-out letters. 11. [FDA: Public Safety Notification on Exosome Products (6 December 2019)](https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-products). US position on exosome products; IND questions. 12. [FDA: Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes). Dated 22 July 2020, current as of 9 April 2024; US context only. Related guides: [clinical trial registration versus approval](https://stemcell-seoul.com/clinical-trial-registration-vs-approval/), [the exosome product evidence checklist](https://stemcell-seoul.com/exosome-product-evidence-checklist/) and [safety and risks](https://stemcell-seoul.com/safety-and-risks/). These records answer different regulatory questions. Personal suitability requires clinical assessment. ## Is stem cell or exosome treatment FDA approved? Source: https://stemcell-seoul.com/is-it-fda-approved/ Updated: 2026-10-18 No exosome product holds United States FDA approval for any indication[1], and no stem-cell product is FDA approved for a cosmetic indication. The FDA maintains a standing consumer alert covering regenerative medicine products including stem cells and exosomes. Two further points make the answer more useful than a flat no: American approval status would not determine Korean legality in any case, and “approved,” “cleared” and “unapproved but marketed” are three different states that clinic copy routinely collapses into one. Figure: Three circular seals in red, blue and amber Primary source [Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes): U.S. Food and Drug Administration Scope of this source: U.S. regulatory context only. Does not establish Korean legal status. ### What the terms actually mean Figure: FDA approval, device clearance and marketing status are distinct. State 1 #### Approved The FDA reviewed evidence of safety and effectiveness for a stated indication and authorised marketing for it. Does not mean: That the product is safe or effective for anything outside that stated indication. State 2 #### Cleared (510(k)) A device was shown substantially equivalent to an already-marketed device. Common for aesthetic energy devices. Does not mean: That an independent trial established effectiveness. Clearance is a comparison, not a proof. State 3 #### Marketed without approval The product is being sold. Some such products are subject to enforcement discretion; some are simply unapproved. Does not mean: Anything at all about safety or effectiveness. Availability is not authorisation. Check the named device’s FDA clearance record and its specified intended use. No exosome product holds FDA approval. For an NCT number, check [how to read a clinical trial registration](https://stemcell-seoul.com/clinical-trial-registration-vs-approval/) and check the separate regulator record. If the claim names a specific product or lot, use the [five-record exosome product checklist](https://stemcell-seoul.com/exosome-product-evidence-checklist/) to keep product identity, processing and documentation connected. ### Exosomes The position is stated directly in the review literature: there are currently no FDA-approved exosomes, and the outstanding obstacles are inconsistent isolation methods, source variability, and the absence of clinical trials establishing long-term safety and efficacy[1]. A 2025 comprehensive review of aesthetic use reaches a compatible conclusion from the other direction: early evidence is encouraging across several indications, and the lack of standardisation in production and application limits what can currently be concluded[3]. Early clinical findings do not establish FDA approval. Product approval and evidence of benefit are separate questions. ### Stem cells for cosmetic indications There is no approved stem-cell product for cosmetic use. The FDA’s consumer alert on regenerative medicine products exists precisely because products in this class are marketed directly to consumers ahead of that authorisation, and clinical commentary has repeatedly described the resulting gap between what is sold and what is established[4]. FDA-approved medicines include topical minoxidil and oral finasteride for their labelled populations; certain low-level light devices are FDA-cleared for specified pattern-hair-loss indications[2]. If a clinic proposes an unapproved option first, the reasonable question is what happened to [the approved ones](https://hifuseoul.com/procedures/hair-loss-treatment-seoul/). ### In short - No exosome product is FDA approved for any indication. - No stem-cell product is FDA approved for a cosmetic indication. - "FDA cleared" applies to devices found substantially equivalent to existing ones; it is not the same claim as approval. - US approval status is not evidence of Korean legality, and Korean legality is not evidence of US approval. They are separate systems answering separate questions. - Availability is not authorisation. A product being purchasable says nothing about whether it was reviewed. ### Why American status is not the whole question in Korea Readers frequently treat FDA approval as a universal seal. It is not: it is one jurisdiction’s determination about one product for one indication. Korea regulates advanced regenerative medicine under [its own statutory framework](https://stemcell-seoul.com/korea-regenerative-medicine-law/), with designation and review requirements for interventions within its defined scope. Specified minimally manipulated cell and tissue procedures are excluded; Korean records establish Korean regulatory status. The corollary matters for medical tourists. A clinic that answers a regulatory question by pointing at a foreign regulator has changed the subject. The critical review literature on stem cell tourism notes that the clinics offering these interventions are concentrated where oversight is lighter, and that patients travelling to them are frequently given little information about either the therapy or the trip[5]. If an approved treatment exists for your diagnosis, that is where a careful discussion usually starts. Unapproved options are not automatically wrong, but they should be a considered second step rather than an unexplained first one. ### References 1. Haykal D, Wyles S, Garibyan L, Cartier H, Gold M. Exosomes in Cosmetic Dermatology: A Review of Benefits and Challenges. *J Drugs Dermatol.* 2025;24(1):12-18. [doi:10.36849/JDD.8872](https://doi.org/10.36849/JDD.8872) · [PMID:39761139](https://pubmed.ncbi.nlm.nih.gov/39761139/) 2. Nestor MS, Ablon G, Gade A, Han H, Fischer DL. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. *J Cosmet Dermatol.* 2021;20(12):3759-3781. [doi:10.1111/jocd.14537](https://doi.org/10.1111/jocd.14537) · [PMID:34741573](https://pubmed.ncbi.nlm.nih.gov/34741573/) 3. Shah M, Dukharan V, Broughton L, et al. Exosomes for Aesthetic Dermatology: A Comprehensive Literature Review and Update. *J Cosmet Dermatol.* 2025;24(1):e16766. [doi:10.1111/jocd.16766](https://doi.org/10.1111/jocd.16766) · [PMID:39764639](https://pubmed.ncbi.nlm.nih.gov/39764639/) 4. Ikonomou L, Weiss DJ. Turning the Tide on Unproven Cell-Based Interventions. *Chest.* 2020;157(4):774-775. [doi:10.1016/j.chest.2019.10.035](https://doi.org/10.1016/j.chest.2019.10.035) · [PMID:32252930](https://pubmed.ncbi.nlm.nih.gov/32252930/) 5. Lyons S, Salgaonkar S, Flaherty GT. International stem cell tourism: a critical literature review and evidence-based recommendations. *Int Health.* 2022;14(2):132-141. [doi:10.1093/inthealth/ihab050](https://doi.org/10.1093/inthealth/ihab050) · [PMID:34415026](https://pubmed.ncbi.nlm.nih.gov/34415026/) ## Stem cell therapy in the US: the FDA rules and the new state laws Source: https://stemcell-seoul.com/is-stem-cell-therapy-legal-in-the-us/ Updated: 2026-10-24 Federal rules in 21 CFR Part 1271 sort human cell and tissue products: one that meets all four criteria in § 1271.10(a) is regulated solely under section 361 of the Public Health Service Act, and one that does not, and has no exception, is regulated as a drug, device or biological product (§ 1271.20). Since 2024 Utah, Florida and Wyoming have added statutes that set notice, consent and sourcing conditions for some stem cell therapies, and Montana’s rules for experimental treatment centers took effect on 25 July 2026. Figure: Diagram of the top of the Utah stem cell notice drawn to scale: a sheet 8.5 inches wide with its opening line, THIS NOTICE MUST BE PROVIDED TO YOU UNDER UTAH LAW, in 40-point type, beside five requirements of Utah Code section 58-1-512: type at least 40 point, paper at least 8.5 by 11 inches, display at the entrance and where patients see it, the notice in any advertisement for the therapy, and signed consent before the therapy The opening line of Utah’s notice at 40 points on a letter-size sheet, drawn to one scale. ### The federal rules: section 361 or drug and biologic rules Under [21 CFR 1271.10(a)](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271), a human cell or tissue product (HCT/P) is regulated solely under section 361 and Part 1271 if it meets all four criteria: it is minimally manipulated; it is “intended for homologous use only”; it is not combined with another article, apart from water, crystalloids or a sterilizing, preserving or storage agent whose addition “does not raise new clinical safety concerns with respect to the HCT/P”; and either it has no systemic effect and does not depend on the metabolic activity of living cells for its primary function, or it does and is for autologous use, for a first- or second-degree blood relative, or for reproductive use. The establishment that makes it registers with FDA and lists each HCT/P (§ 1271.10(b)). Section 1271.15(b) exempts from Part 1271 an establishment that removes cells or tissue from a person and implants them into the same person during the same surgical procedure. A product that fails a criterion and fits no exception “will be regulated as a drug, device, and/or biological product” (§ 1271.20). An [FDA page for CBER-regulated products](https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/investigational-new-drug-applications-inds-cber-regulated-products) describes an investigational new drug application (IND) as a clinical study sponsor’s request “to administer an investigational drug or biological product to humans”; [reading FDA records on stem cell products](https://stemcell-seoul.com/fda-registered-vs-approved-records/) explains what that record shows. Figure: Flow chart of 21 CFR Part 1271: a product meeting all four criteria of section 1271.10(a) is a section 361 HCT/P; otherwise, without an exception, it is a drug, device or biological product, with an arrow to a box describing an IND as a clinical study sponsor’s request to administer an investigational drug or biological product to humans The four criteria decide which federal category applies. ### State laws since 2024, record by record #### Utah: Code § 58-1-512, stem cell disclosure Utah enacted the section through [S.B. 199](https://le.utah.gov/~2024/bills/sbillenr/SB0199.pdf), in effect from 1 May 2024; [the current text](https://le.utah.gov/xcode/Title58/Chapter1/C58-1-S512_2026050620260506.pdf) took effect on 6 May 2026 (amended by chapter 87, 2026 General Session). It covers a health care provider whose scope of practice includes stem cell therapy, defined as treatment involving “afterbirth placental perinatal stem cells or human cells, tissues, or cellular or tissue-based products.” Before such a therapy the provider gives the patient a written notice that opens “THIS NOTICE MUST BE PROVIDED TO YOU UNDER UTAH LAW.” The notice is on paper at least 8.5 by 11 inches, in at least 40-point type, displayed at the entrance and where patients can see it, and repeated in any advertisement for the therapy. The patient signs a consent form that states the nature of the treatment, including its “United States Food and Drug Administration approval status”, the anticipated results, the recognised alternatives, and the serious possible risks and anticipated benefits. The 2026 text adds a condition for suppliers: before supplying cells or tissue, they obtain the provider’s written confirmation that patients will receive the notice. The section does not apply to a provider “who has obtained approval for an investigational new drug or device” from FDA for these products, or to one working on behalf of an institution certified by the Foundation for the Accreditation of Cellular Therapy, the Blood and Marrow Transplant Clinical Trials Network, the Association for the Advancement of Blood and Biotherapies or another body the state division names. #### Florida: sections 458.3245 and 459.0127 (2025) and 461.011 (2026) [SB 1768](https://www.flsenate.gov/Session/Bill/2025/1768) (chapter 2025-185) took effect on 1 July 2025 and created parallel sections for medical and osteopathic physicians. They cover stem cell therapy within the physician’s scope of practice and “related to orthopedics, wound care, or pain management.” The cells must be retrieved, manufactured and stored in a facility registered and regulated by FDA and certified or accredited by the National Marrow Donor Program, the World Marrow Donor Association, the Association for the Advancement of Blood and Biotherapies or the American Association of Tissue Banks. Each lot needs a post-thaw viability report sent to the physician before use, and the supply contract requires the facility to give the physician its accreditation details. Advertisements carry a notice that opens “THIS NOTICE MUST BE PROVIDED TO YOU UNDER FLORIDA LAW,” and the patient signs a consent form with five required statements. [SB 1092](https://www.flsenate.gov/Session/Bill/2026/1092) (chapter 2026-124) became law on 11 June 2026 and created section 461.011 for podiatric physicians. It uses the term “cellular or tissue-based products” and lists “connective tissue, ligament, and tendon repair; wound care; or pain management,” with the same facility, viability report, advertising notice and consent requirements. #### Wyoming: the Stem Cell Freedom Act (2026) [Enrolled Act No. 31](https://www.wyoleg.gov/2026/Enroll/SF0048.pdf) (SF0048) created W.S. 35-4-1101 to 35-4-1106, effective 1 July 2026. It defines stem cell therapy as treatment involving “autologous mesenchymal stem cells,” including their cultural expansion. Its conditions: the therapy is “conducted in accordance with a current institutional review board approval” or is an investigational drug, biological product or device, a term whose definition in the Act requires completion of phase 1 of a clinical trial and that the product “remains under investigation in a clinical trial”; the cells are made under current good manufacturing practice; a physician-patient relationship exists; the physician is registered with the Wyoming Board of Medicine; and the patient gives written informed consent acknowledging four points, including the patient’s financial responsibility. The Act directs the Board to operate and publish a public registry of physicians registered under it. #### Montana: experimental treatment centers (2026) Montana’s Department of Public Health and Human Services adopted rules for “experimental treatment centers” in [MAR Notice No. 2026-427.2](https://dphhs.mt.gov/assets/rules/2026-427-Adp-Arm.pdf), effective 25 July 2026. The notice quotes the state definition of experimental treatment in 50-12-102(1), MCA: a medical intervention “involving an investigational drug, biological product, device, or other treatment that has successfully completed phase 1 of a clinical trial.” It does not mention stem cells. Each center keeps a file for every patient that includes the treating practitioner’s documentation that the patient meets the criteria, informed consent under 50-12-105, MCA, and the patient agreement. Figure: Five cards summarising Utah Code 58-1-512, Florida sections 458.3245, 459.0127 and 461.011, the Wyoming Stem Cell Freedom Act and Montana MAR Notice 2026-427.2: who each covers and what each puts in front of a patient Each state record names its own practitioners, products and patient documents. ### Enforcement and litigation in 2026 FDA’s Center for Biologics Evaluation and Research applied the § 1271.10(a) criteria in two 2026 warning letters about products derived from umbilical cord or cord blood: CBER 25-712579, dated 11 February 2026, and CBER 26-728085, dated 26 May 2026. The February letter states that the product fails the minimal manipulation criterion and the homologous use criterion; the May letter cites the homologous use criterion. Both state that the product is a drug and a biological product and is not regulated solely under section 361. Letters can be found by reference number in [FDA’s warning letter search](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters). Private lawsuits are a second record. [A 2026 analysis in Cytotherapy](https://pubmed.ncbi.nlm.nih.gov/42556174/) used a class action lawsuit as an example of patient-initiated lawsuits over unproven “stem cell” interventions, and discussed lessons for coordinated enforcement and litigation. Figure: Timeline from May 2024 to July 2026 of state measures in Utah, Florida, Wyoming and Montana and two FDA warning letters dated February and May 2026 State measures and federal warning letters ran side by side in 2026. ### Records to ask for on each route - **Utah or Florida statute:** the notice, posted or in the advertisement, and the signed consent form with the statements the section lists. In Florida, also the facility’s name, its certifying or accrediting body and the post-thaw viability report for the lot; the statute requires the facility to give these to the physician. - **Wyoming:** the physician’s entry in the Board of Medicine registry, the review board or investigational record the therapy runs under, and the signed consent. - **Clinical study:** the IND number and the trial registration; [how to read a trial registration record](https://stemcell-seoul.com/clinical-trial-registration-vs-approval/) covers the second. - **Montana experimental treatment center:** the informed consent and the patient agreement, both kept in the center’s file for the patient. - **Any route:** FDA’s warning letter search for the company named on the product. ### How Korea handles the same question Korea uses one national statute instead of a federal and state split. Its [Act on the Safety of and Support for Advanced Regenerative Medicine and Advanced Biological Products](https://law.go.kr/LSW/lsInfoP.do?ancYnChk=0&chrClsCd=010202&efYd=20261008&lsiSeq=285347&urlMode=lsInfoP), in the version marked [시행 2026. 10. 8.] [법률 제21525호, 2026. 4. 7., 타법개정], routes cell-based interventions through designated institutions and committee-reviewed research or treatment plans, and its definition of treatment recipients covers serious, rare and intractable diseases (Article 2(6)). Separate guides cover [the 2026 Korean records and the 2026–2030 plan](https://stemcell-seoul.com/south-korea-stem-cell-therapy-2026/) and [the structure of Korean regenerative medicine law](https://stemcell-seoul.com/korea-regenerative-medicine-law/). For a visitor treated in Korea, the treatment record itself is one more document: [what to ask a Korean clinic for before flying home](https://hifuseoul.com/blog/medical-records-after-skin-treatment-seoul/). ### Frequently asked questions ### Which states added stem cell or experimental treatment measures in 2025 and 2026? Florida created sections 458.3245 and 459.0127, in effect from 1 July 2025, and section 461.011 for podiatric physicians, law from 11 June 2026. Wyoming’s Stem Cell Freedom Act took effect on 1 July 2026. Utah amended section 58-1-512, first in effect in 2024, with the new text in effect from 6 May 2026. Montana’s rules for experimental treatment centers took effect on 25 July 2026. ### What does the FDA test in 21 CFR 1271.10(a) check? Four criteria: the product is minimally manipulated; it is intended for homologous use only; it is not combined with another article apart from water, crystalloids or a sterilizing, preserving or storage agent that raises no new clinical safety concerns; and it has no systemic effect and does not depend on the metabolic activity of living cells for its primary function, unless the use is autologous, in a first- or second-degree blood relative, or reproductive. ### What is Wyoming’s stem cell registry? The Stem Cell Freedom Act directs the Wyoming Board of Medicine to “operate and publish a public registry of qualified physicians registered to perform stem cell therapy.” ### Primary sources 1. [21 CFR Part 1271: Human cells, tissues, and cellular and tissue-based products (eCFR)](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271). Sections 1271.10, 1271.15 and 1271.20; eCFR current to 22 October 2026. 2. [FDA: Investigational New Drug Applications (INDs) for CBER-Regulated Products](https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/investigational-new-drug-applications-inds-cber-regulated-products). What an IND is; content current as of 4 September 2026. 3. [Utah Code § 58-1-512, Stem cell disclosure (version in effect 6 May 2026)](https://le.utah.gov/xcode/Title58/Chapter1/C58-1-S512_2026050620260506.pdf). Notice, consent, advertising, supplier condition and exceptions. 4. [Utah S.B. 199, Placental Tissue Amendments, 2024 General Session (enrolled copy)](https://le.utah.gov/~2024/bills/sbillenr/SB0199.pdf). Enactment of § 58-1-512 and its 1 May 2024 effective date. 5. [Florida Senate: CS/CS/SB 1768 (2025), Stem Cell Therapy, chapter 2025-185](https://www.flsenate.gov/Session/Bill/2025/1768). Sections 458.3245 and 459.0127; effective 1 July 2025. 6. [Florida Senate: CS/CS/SB 1092 (2026), Podiatric Medicine, chapter 2026-124](https://www.flsenate.gov/Session/Bill/2026/1092). Section 461.011; bill history and effective date. 7. [Wyoming Legislature: SF0048, Enrolled Act No. 31, Senate (2026 Budget Session)](https://www.wyoleg.gov/2026/Enroll/SF0048.pdf). W.S. 35-4-1101 to 35-4-1106 and the Board of Medicine registry. 8. [Wyoming Legislative Service Office: summary of SF0048](https://www.wyoleg.gov/2026/Summaries/SF0048.pdf). Chapter 64 and the 1 July 2026 effective date. 9. [Montana Department of Public Health and Human Services: MAR Notice No. 2026-427.2, experimental treatment centers](https://dphhs.mt.gov/assets/rules/2026-427-Adp-Arm.pdf). Adopted rules, effective 25 July 2026, and the 50-12-102(1), MCA definition. 10. [FDA: Warning letters search](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters). Letters CBER 25-712579 (11 February 2026) and CBER 26-728085 (26 May 2026). 11. [Korea: Act on the Safety of and Support for Advanced Regenerative Medicine and Advanced Biological Products](https://law.go.kr/LSW/lsInfoP.do?ancYnChk=0&chrClsCd=010202&efYd=20261008&lsiSeq=285347&urlMode=lsInfoP). Version [시행 2026. 10. 8.] [법률 제21525호, 2026. 4. 7., 타법개정]; Article 2(6) definition of treatment recipients. 12. Alonzo M, Grilley BJ, Weiss DJ, Ikonomou L. Litigating the hype: the Lung Health Institute class action and its implications. Cytotherapy. 2026;28(10):102902. [PMID 42556174](https://pubmed.ncbi.nlm.nih.gov/42556174/) · [doi:10.1016/j.jcyt.2026.102902](https://doi.org/10.1016/j.jcyt.2026.102902). Patient-initiated litigation. Related guides: [FDA status of stem cell and exosome treatment](https://stemcell-seoul.com/is-it-fda-approved/), [the exosome product evidence checklist](https://stemcell-seoul.com/exosome-product-evidence-checklist/) and [safety and risks](https://stemcell-seoul.com/safety-and-risks/). A consultation in Seoul starts from your own skin, medical history and examination. ## How Korean law regulates regenerative medicine Source: https://stemcell-seoul.com/korea-regenerative-medicine-law/ Updated: 2026-10-18 Korea governs advanced regenerative medicine through a dedicated statute: 첨단재생의료 및 첨단바이오의약품 안전 및 지원에 관한 법률, the Act on the Safety of and Support for Advanced Regenerative Medicine and Advanced Biological Products. The version currently in force is marked [시행 2026. 10. 8.] [법률 제21525호, 2026. 4. 7., 타법개정]. Its structure matters more than its detail for a patient: interventions within the Act’s advanced regenerative medicine pathway require institutional designation and plan review, whether conducted as clinical research or treatment. The statutory definition excludes specified minimally manipulated cell and tissue procedures. Cosmetic purpose alone does not determine whether an intervention is covered. The statute’s existence is not evidence that any particular clinic has passed those gates. That is a document a clinic either can or cannot show you. Figure: Two blue gates on a branching yellow road between red mountains Primary source [첨단재생의료 및 첨단바이오의약품 안전 및 지원에 관한 법률 (Act on the Safety of and Support for Advanced Regenerative Medicine and Advanced Biological Products)](https://law.go.kr/LSW/lsInfoP.do?ancYnChk=0&chrClsCd=010202&efYd=20261008&lsiSeq=285347&urlMode=lsInfoP): Korea Ministry of Government Legislation (국가법령정보센터) Scope of this source: In force: 8 October 2026; Act No. 21525, amended 7 April 2026. Primary source [식품의약품안전처 (Ministry of Food and Drug Safety)](https://www.mfds.go.kr/index.do): Republic of Korea Scope of this source: The Korean regulator for drugs, biologics and medical devices. Its existence establishes no status for any particular product, and product authorisation is a separate question from whether a clinic may perform a given procedure. ### The shape of the framework Institutional designation and plan review apply to interventions within the Act’s advanced regenerative medicine pathway. Scope exclusions are separate from designation and from product approval; an excluded procedure is not thereby approved as a product. Figure: Interventions within the Act’s advanced regenerative medicine pathway require institutional designation and plan review. Specified minimally manipulated cell or tissue procedures are excluded from the statutory definition. Product authorisation follows a separate pathway. Intervention within the Act’s defined scope 1. Gate 1 재생의료기관: designation of the institution 2. Gate 2 재생의료 심의위원회: committee review of the plan Conducted as one of 재생의료 임상연구: conducted as clinical research 재생의료 치료: conducted as treatment 첨단바이오의약품: product track: separate authorisation as a biological product Cosmetic-only marketing claim: A marketing claim alone establishes neither legal scope nor authorisation. Two further features are worth naming. The statute distinguishes regenerative medicine conducted as clinical research (재생의료 임상연구) from regenerative medicine conducted as treatment (재생의료 치료), a distinction that determines what may be charged for and on what basis a patient is enrolled. And it runs alongside a separate track for advanced biological products (첨단바이오의약품), which are authorised as products rather than permitted as procedures. A material may therefore be lawfully manufactured without any given clinical use of it being authorised, and vice versa. ### What the framework does not establish The existence of a regulatory framework does not establish the status of a specific clinic or product: - that the clinic holds designation as a 재생의료기관; - that any plan of theirs has been reviewed or approved by the committee; - that a given material they use is an authorised 첨단바이오의약품; - that a proposed intervention falls within the scope of whatever they are designated for; - that an intervention marketed for cosmetic purposes has been through any of this at all. Each of those is a separate fact with a separate document behind it. A clinic that is operating within the framework can produce the relevant one; that is what designation and review produce. The [questions to ask a clinic](https://stemcell-seoul.com/questions-to-ask-a-clinic/) can help clarify those records. ### What to hold on to - The current statute in force is marked 시행 2026. 10. 8., 법률 제21525호, 2026. 4. 7. 타법개정. - Interventions within the Act’s advanced regenerative medicine pathway require institutional designation and plan review. Specified minimally manipulated cell and tissue procedures are excluded. - Clinical research and treatment are distinguished in law, and the distinction affects what a patient is agreeing to. - Advanced biological products are authorised on a separate product track from the procedures that use them. - None of the above tells you the status of any individual clinic. Ask for the document. ### Why Korea specifically attracts this question Korea has [a large aesthetic medicine sector](https://hifuseoul.com/blog/board-certified-dermatologist-korea/) and a long history in this particular field. A bioethics analysis published in 2017 examined how stem cell marketing developed in South Korea and the United States, describing both as home to significant industries selling cell-based interventions ahead of conclusive evidence, and tracing the social and regulatory conditions that permitted it[1]. That history is part of why the current statutory framework exists, and part of why a careful reader should ask specific questions rather than rely on national reputation in either direction. For readers travelling to Korea, the relevant literature is broader than Korean law. A critical review of international stem cell tourism found that clinics offering these therapies cluster in jurisdictions with lighter oversight, that documented complications include infection, rejection and tumorigenesis, and that clinics generally provide little pre-travel health information[2]. Commentary in the clinical literature has argued that the response has to come jointly from regulators, professional societies and physicians rather than from any one of them[3]. The [safety and risks page](https://stemcell-seoul.com/safety-and-risks/) covers the documented harms in more detail. Regulatory questions and clinical questions are different. Whether something is permitted does not answer whether it is indicated for you, and for most skin and hair concerns the better-evidenced options are not regenerative ones. ### References 1. Sipp D. Cell Churches and Stem Cell Marketing in South Korea and the United States. *Dev World Bioeth.* 2017;17(3):167-172. [doi:10.1111/dewb.12120](https://doi.org/10.1111/dewb.12120) · [PMID:27214044](https://pubmed.ncbi.nlm.nih.gov/27214044/) 2. Lyons S, Salgaonkar S, Flaherty GT. International stem cell tourism: a critical literature review and evidence-based recommendations. *Int Health.* 2022;14(2):132-141. [doi:10.1093/inthealth/ihab050](https://doi.org/10.1093/inthealth/ihab050) · [PMID:34415026](https://pubmed.ncbi.nlm.nih.gov/34415026/) 3. Ikonomou L, Weiss DJ. Turning the Tide on Unproven Cell-Based Interventions. *Chest.* 2020;157(4):774-775. [doi:10.1016/j.chest.2019.10.035](https://doi.org/10.1016/j.chest.2019.10.035) · [PMID:32252930](https://pubmed.ncbi.nlm.nih.gov/32252930/) ## PRP and polynucleotides: evidence and comparisons Source: https://stemcell-seoul.com/prp-and-polynucleotides/ Updated: 2026-10-24 PRP, polynucleotides and exosome products differ in material, preparation and studied use. PRP injection studies in pattern hair loss and studies of exosome-containing products with microneedling for facial ageing answer different questions. Their results do not establish which treatment is better for the same concern.[1, 9] Figure: An upright tube with amber plasma, a thin white interface and a red lower layer ### Platelet-rich plasma #### What it is Figure: After centrifugation, the buffy coat lies between plasma and red cells and contains leukocytes and platelets. 1. Plasma containing platelets The upper fraction; collection and further centrifugation depend on the system. 2. Buffy coat: leukocytes and platelets Collection of this layer varies with the preparation system. 3. Red cells The dense lower fraction, discarded. **The point:** PRP is plasma enriched with platelets. Platelet-containing plasma is collected and processed according to the preparation system; leukocyte content varies. PRP is prepared by concentrating platelets in plasma from the patient’s blood. The collected fraction, further centrifugation and leukocyte content depend on the preparation system. The buffy coat contains leukocytes and platelets; it is not interchangeable with the final PRP preparation. Platelets are anucleate cell fragments, not stem cells. Preparation is not standardised. Studies differ in whether the platelets are activated, in centrifugation protocol, in final platelet concentration and in injection schedule, a heterogeneity the systematic reviewers name explicitly as a limit on pooling results[1]. Two clinics offering “PRP” may be delivering measurably different preparations. #### What the trials found Cruciani and colleagues’ 2023 review included 27 controlled alopecia trials: 18 androgenetic-alopecia trials with 713 participants and nine alopecia-areata trials with 404 participants. A smaller subset of androgenetic-alopecia trials contributed to the pooled hair-density comparison against saline; the certainty was rated low under GRADE. No serious adverse events were reported, but incomplete reporting and limited follow-up prevent reliable estimates of uncommon harms[1]. A meta-analysis restricted to nine randomised controlled trials in 238 patients with androgenetic alopecia found statistically significant increases in hair density against placebo at three and six months; hair count and hair diameter improved relative to baseline but not significantly relative to placebo[2]. In female pattern hair loss specifically, a meta-analysis of seven studies found increased terminal hair density without a significant increase in hair thickness, and its authors recommended caution pending replication in larger and more representative samples[3]. #### How to read that PRP reviews report increased hair density, with less consistent results for other outcomes. FDA-approved medicines include topical minoxidil and oral finasteride for their labelled populations; certain low-level light devices are FDA-cleared for specified pattern-hair-loss indications[4]. A discussion that reaches PRP without having addressed the approved options has skipped a step. [PRP procedure details](https://hifuseoul.com/procedures/prp-seoul/) ### PDRN and polynucleotides #### What they are PDRN (polydeoxyribonucleotide) is a mixture of deoxyribonucleotides with molecular weights in a defined range, produced from salmon DNA through a controlled purification and sterilisation process designed to eliminate active protein and peptide content that could provoke an immune reaction. Its proposed mechanism is engagement of the adenosine A2A receptor, together with supply of nucleosides and nucleotides to the salvage pathway[5]. A review of its application in skin regeneration describes effects on cell migration, angiogenesis and inflammation across in vitro, in vivo and clinical wound-healing studies[6]. “Polynucleotide” is the broader term now widely used in aesthetic practice. It is important not to assume PDRN’s pharmacology transfers wholesale to every product marketed under the polynucleotide label: the mechanistic literature was built on PDRN specifically, and source material, molecular weight distribution and manufacturing differ between products. #### What the aesthetic evidence shows A systematic review published in 2025 identified nine studies of low and moderate quality covering 219 patients receiving polynucleotide treatment. It reported promising outcomes in reducing wrinkles, improving skin texture and enhancing elasticity, with statistically significant results in several studies, side effects generally mild and transient, and moderate-to-high patient satisfaction, alongside substantial variation in injection areas and technique and limited consensus on optimal use[7]. A parallel review of current practice reached a similar position, noting varying degrees of reported efficacy and the need for further research to establish optimal use[8]. ### Where these two sit - PRP for androgenetic alopecia: multiple meta-analyses of randomised trials; density improves against placebo; certainty graded low; no serious adverse events reported, with incomplete reporting and limited follow-up. - PRP is not a stem cell treatment. It contains platelets, which are anucleate cell fragments. - PDRN has a genuine pharmacology literature centred on adenosine A2A-receptor activation and the nucleotide salvage pathway, developed largely in wound healing. - Polynucleotides in aesthetic use: one systematic review, nine studies, 219 patients, low to moderate quality, no settled protocol. - Neither modality has a universal session count, interval, or duration of effect established by the literature. Protocols quoted as standard are clinic practice, not published consensus. ### PRP vs exosomes: comparing like-for-like evidence The 2023 Cruciani review evaluated PRP injections for alopecia. In the androgenetic-alopecia studies, pooled hair-density results favoured PRP over saline, with low-certainty evidence. Preparations and schedules varied.[1] Park’s 2023 trial studied 28 people with facial skin ageing. An exosome-containing solution derived from human adipose tissue was applied with microneedling on one side of the face; saline with microneedling was used on the other. At 12 weeks, several skin measures improved more on the exosome-solution side. This was a small study of a combined procedure, not a comparison with PRP.[9] These are separate evidence summaries, not a direct PRP-versus-exosome trial. Compare the same indication, product, administration route, patient population, outcome and follow-up before drawing a treatment ranking. For the narrower question of RF microneedling with topical products, see [RF microneedling and topical exosome products: evidence and limitations](https://hifuseoul.com/blog/rf-microneedling-exosome-regenerative-combination-seoul/) ### Polynucleotide injections: terminology and questions to ask PDRN means polydeoxyribonucleotide. The 2017 pharmacology review concerns a defined DNA preparation; the 2025 polynucleotide review covers aesthetic studies with varied injection methods. A shared label does not make the products or their evidence equivalent.[5, 7] #### Are PRP, polynucleotides and exosomes interchangeable? No. PRP is a platelet preparation from blood; polynucleotide products contain DNA polymers; exosomes are cell-released vesicles. Evidence for one material and route does not establish the effect of another.[1, 5, 10] #### What product and administration details should I request? Ask for the product name, manufacturer, source material, concentration and amount, and whether it will be injected or applied topically. Request the treatment area, session schedule, accompanying procedures and a study using the same product and route for your concern. Both of these are injectable procedures whose appropriateness depends on the diagnosis, your medication list and your bleeding risk. For hair loss in particular, establishing the pattern and cause comes before choosing among treatments. ### References 1. Cruciani M, Masiello F, Pati I, Marano G, Pupella S, De Angelis V. Platelet-rich plasma for the treatment of alopecia: a systematic review and meta-analysis. *Blood Transfus.* 2023;21(1):24-36. [doi:10.2450/2021.0216-21](https://doi.org/10.2450/2021.0216-21) · [PMID:34967722](https://pubmed.ncbi.nlm.nih.gov/34967722/) 2. Zhang X, Ji Y, Zhou M, et al. Platelet-Rich Plasma for Androgenetic Alopecia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *J Cutan Med Surg.* 2023;27(5):504-508. [doi:10.1177/12034754231191461](https://doi.org/10.1177/12034754231191461) · [PMID:37533146](https://pubmed.ncbi.nlm.nih.gov/37533146/) 3. de Oliveira AFQ, Arcanjo FPN, Rodrigues MRP, Rosa e Silva AA, Hall PR. Use of autologous platelet-rich plasma in androgenetic alopecia in women: a systematic review and meta-analysis. *J Dermatolog Treat.* 2023;34(1):2138692. [doi:10.1080/09546634.2022.2138692](https://doi.org/10.1080/09546634.2022.2138692) · [PMID:36264022](https://pubmed.ncbi.nlm.nih.gov/36264022/) 4. Nestor MS, Ablon G, Gade A, Han H, Fischer DL. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. *J Cosmet Dermatol.* 2021;20(12):3759-3781. [doi:10.1111/jocd.14537](https://doi.org/10.1111/jocd.14537) · [PMID:34741573](https://pubmed.ncbi.nlm.nih.gov/34741573/) 5. Squadrito F, Bitto A, Irrera N, et al. Pharmacological Activity and Clinical Use of PDRN. *Front Pharmacol.* 2017;8:224. [doi:10.3389/fphar.2017.00224](https://doi.org/10.3389/fphar.2017.00224) · [PMID:28491036](https://pubmed.ncbi.nlm.nih.gov/28491036/) 6. Galeano M, Pallio G, Irrera N, et al. Polydeoxyribonucleotide: A Promising Biological Platform to Accelerate Impaired Skin Wound Healing. *Pharmaceuticals (Basel).* 2021;14(11):1103. [doi:10.3390/ph14111103](https://doi.org/10.3390/ph14111103) · [PMID:34832885](https://pubmed.ncbi.nlm.nih.gov/34832885/) 7. Lampridou S, Bassett S, Cavallini M, Christopoulos G. The Effectiveness of Polynucleotides in Esthetic Medicine: A Systematic Review. *J Cosmet Dermatol.* 2025;24(2):e16721. [doi:10.1111/jocd.16721](https://doi.org/10.1111/jocd.16721) · [PMID:39645667](https://pubmed.ncbi.nlm.nih.gov/39645667/) 8. Lee KWA, Chan KWL, Lee A, et al. Polynucleotides in Aesthetic Medicine: A Review of Current Practices and Perceived Effectiveness. *Int J Mol Sci.* 2024;25(15):8224. [doi:10.3390/ijms25158224](https://doi.org/10.3390/ijms25158224) · [PMID:39125793](https://pubmed.ncbi.nlm.nih.gov/39125793/) 9. Park GH, Kwon HH, Seok J, et al. Efficacy of combined treatment with human adipose tissue stem cell-derived exosome-containing solution and microneedling for facial skin aging: A 12-week prospective, randomized, split-face study. *J Cosmet Dermatol.* 2023;22(12):3418-3426. [doi:10.1111/jocd.15872](https://doi.org/10.1111/jocd.15872) · [PMID:37377400](https://pubmed.ncbi.nlm.nih.gov/37377400/) 10. Welsh JA, Goberdhan DCI, O'Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. *J Extracell Vesicles.* 2024;13(2):e12404. [doi:10.1002/jev2.12404](https://doi.org/10.1002/jev2.12404) · [PMID:38326288](https://pubmed.ncbi.nlm.nih.gov/38326288/) ## Choosing a stem cell clinic in Seoul: eight questions to ask first Source: https://stemcell-seoul.com/questions-to-ask-a-clinic/ Updated: 2026-10-20 Before agreeing to a procedure, ask what it contains, what authorisation applies, what evidence supports it and who manages complications. Request product records and a written follow-up plan. Figure: Two speech bubbles above three checked boxes ### What exactly is being injected, and where did it come from? Why it matters. The four families of regenerative product differ in what they contain. "Regenerative" alone does not identify the material. A substantive answer sounds like. A named product or preparation, its source, and whether it is autologous or derived from cultured cells. Treat with caution. "A regenerative cocktail", "growth factors", or a brand name with no description of contents. ### Is this conducted as treatment or as clinical research, and under what authorisation? Why it matters. Korean law distinguishes the two; interventions within its advanced regenerative medicine pathway require institutional designation and plan review. A substantive answer sounds like. A direct answer naming the route, and a willingness to show the relevant designation or approval document. Treat with caution. Deflection to the clinic’s reputation, years of experience, or the number of patients treated. ### What is the strongest published evidence for this, in my indication? Why it matters. Evidence for one indication does not carry to another, and mechanism studies are not clinical evidence. A substantive answer sounds like. A named study design and its limits: "there are meta-analyses in pattern hair loss and they graded certainty as low" is a good answer. Treat with caution. "Studies show", "clinically proven", or citations to laboratory work presented as clinical results. ### What are the approved treatments for my diagnosis, and why are we not starting there? Why it matters. For several common indications, treatments with regulatory approval exist. Skipping them needs a reason. A substantive answer sounds like. The approved options named, with a specific clinical reason they are unsuitable or have been tried. Treat with caution. The approved options not mentioned at all, or dismissed generically as outdated. ### What is the realistic range of outcomes, including no visible change? Why it matters. Trials in this field report modest effects on some measures and none on others. A substantive answer sounds like. A range that includes disappointment, and a stated point at which you would stop. Treat with caution. A single confident outcome, before-and-after photographs offered as the answer, or any guarantee. ### What are the specific risks for me, given my medications and history? Why it matters. Bleeding risk, immune conditions, scarring history and allergies all change the assessment. A substantive answer sounds like. Questions back to you about your medication list and history before any answer is given. Treat with caution. "It is completely safe, it is natural", or "there are no side effects". ### Who manages a complication, and how do I reach them after I go home? Why it matters. For travelling patients this is the risk most often left unplanned. A substantive answer sounds like. A named contact route, written records of what was administered, and an expectation of follow-up. Treat with caution. Vagueness, or an assumption that your home clinician will handle it without records. ### Can I have in writing what was administered? Why it matters. A clinician treating a complication needs the material, source and dose. "Exosomes" is not sufficient. A substantive answer sounds like. A written record given without hesitation. Treat with caution. Reluctance, or an offer to describe it verbally only. ### Why question one is the hard one “What exactly is being injected” sounds basic and is frequently the question that does not get a clean answer. For exosome preparations in particular, isolation and characterisation methods vary between suppliers, and reviews of cosmetic use name that variability (inconsistent isolation, source variability, absent standardisation) as an unresolved problem in the field[1]. The research community has published successive editions of minimum reporting standards partly because laboratories needed a shared definition to compare results at all[3]. If the field needs a standard to agree on terms, a clinic ought to be able to say which material it is using. The same applies at the better-evidenced end. PRP preparation varies across published trials in activation, centrifugation and schedule, which the systematic reviewers cite as a limit on pooling their results[4]. Asking what protocol a clinic uses is a reasonable question with a real answer. ### If you are travelling for this Questions seven and eight carry more weight for you than for a local patient. The critical review literature on stem cell tourism describes clinics that provide little pre-travel health information and patients who return home to complications that nobody has planned for[2]. Get the written record before you leave, not after something goes wrong. Identify, before you travel, which clinician at home would manage a complication, and tell them what you are considering. Planning the consultation itself, including what to share about earlier procedures, is covered in [Delight Dermatology’s notes for planning a consultation from abroad](https://hifuseoul.com/guides/english-speaking-dermatologist-seoul/). ### One thing to notice about a good clinic A clinic answering these well will sometimes tell you not to have the procedure. That is a positive signal rather than a lost sale: the approved treatments for your diagnosis may not have been tried, the diagnosis itself may not be settled, or the expected benefit may not justify the cost and the needle. A consultation that cannot end in “not this” is not really a consultation. ### Questions to ask about a treatment quote #### What exact product and procedure does this quote cover? Request an itemised quote naming the product or preparation, amount, treatment area, administration route and any combined procedure. Ask what would change the total. #### Is the quote per session or for a complete course? Ask how many sessions are included, their proposed spacing, when the plan will be reassessed, and how unused sessions or changes to the plan are handled. #### Which consultation, follow-up and additional charges are included? Ask whether consultation, tests, anaesthesia, medicines and follow-up are included or charged separately. Request written terms for additional visits and management of complications. #### What documentation supports the proposed treatment? Request the product information, relevant authorisation or research documents, and published evidence for the proposed indication and administration route. Ask for the consent form and a copy of the treatment record. To explore other procedures by concern, [Browse Seoul procedure information by concern](https://hifuseoul.com/procedures/) Bring this checklist to your consultation. ### References 1. Haykal D, Wyles S, Garibyan L, Cartier H, Gold M. Exosomes in Cosmetic Dermatology: A Review of Benefits and Challenges. *J Drugs Dermatol.* 2025;24(1):12-18. [doi:10.36849/JDD.8872](https://doi.org/10.36849/JDD.8872) · [PMID:39761139](https://pubmed.ncbi.nlm.nih.gov/39761139/) 2. Lyons S, Salgaonkar S, Flaherty GT. International stem cell tourism: a critical literature review and evidence-based recommendations. *Int Health.* 2022;14(2):132-141. [doi:10.1093/inthealth/ihab050](https://doi.org/10.1093/inthealth/ihab050) · [PMID:34415026](https://pubmed.ncbi.nlm.nih.gov/34415026/) 3. Welsh JA, Goberdhan DCI, O'Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. *J Extracell Vesicles.* 2024;13(2):e12404. [doi:10.1002/jev2.12404](https://doi.org/10.1002/jev2.12404) · [PMID:38326288](https://pubmed.ncbi.nlm.nih.gov/38326288/) 4. Cruciani M, Masiello F, Pati I, Marano G, Pupella S, De Angelis V. Platelet-rich plasma for the treatment of alopecia: a systematic review and meta-analysis. *Blood Transfus.* 2023;21(1):24-36. [doi:10.2450/2021.0216-21](https://doi.org/10.2450/2021.0216-21) · [PMID:34967722](https://pubmed.ncbi.nlm.nih.gov/34967722/) ## Safety, risks, and what has actually gone wrong Source: https://stemcell-seoul.com/safety-and-risks/ Updated: 2026-10-18 The risk profile is not uniform across this category. The PRP meta-analyses reported no serious adverse events attributable to treatment, with incomplete reporting and limited follow-up, and the polynucleotide review described side effects as generally mild and transient. At the other end, the critical review literature on unproven cell-based interventions documents infection, immune rejection and tumour formation, and neurological complications have been reported and reviewed separately. Before agreeing, identify the material, the responsible clinician and the plan for managing complications after you return home. Figure: A blue shield with red circles inside and outside it Primary source [Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes): U.S. Food and Drug Administration Scope of this source: U.S. regulatory context only. Does not establish Korean legal status. Figure: Reported harms differ by material, preparation and procedure. #### PRP and polynucleotide clinical studies Adverse events reported in the cited reviews. - No serious adverse events were reported in the PRP review. - Polynucleotide side effects described as generally mild and transient across nine studies in 219 patients - Incomplete reporting and limited follow-up prevent reliable estimates of uncommon harms. #### Unproven cell-based interventions Documented in the critical review literature. - Infection introduced during harvest, processing or administration - Immune reactions and rejection - Tumour formation - Neurological complications from preparations given outside clinical research - Absent follow-up: a complication after travelling home often falls to a clinician with no record of what was given ### Safety reporting for PRP and polynucleotides The 2023 systematic review of controlled PRP trials reported no serious adverse events related to PRP injection or to the control treatments[4]. The systematic review of polynucleotides in aesthetic medicine, covering nine studies and 219 patients, described side effects as generally mild and transient[5]. No serious adverse events were reported, but incomplete adverse-event reporting and limited follow-up prevent reliable estimates of uncommon harms. ### What has gone wrong with unproven cell-based interventions The literature here is about cell-based interventions offered outside research frameworks, largely for serious conditions rather than aesthetic ones. It is nonetheless the relevant evidence, because the mechanism of harm follows the material and the oversight rather than the indication. A critical review of international stem cell tourism reports that stem cell therapies offered in this market are associated with complications including infection, rejection and tumorigenesis, that the clinics involved are predominantly located in low- and middle-income countries with lighter regulation, and that they generally do not provide even basic travel health information to the patients they recruit[1]. A review focused on neurology describes a rising pattern of patients with incurable conditions seeking cell preparations outside clinical research, and the neurological complications reported from those activities[2]. Clinical commentary has characterised the sector as one where the corrective has to come from regulators, professional bodies and physicians together[3]. ### The risk that travel adds A patient treated locally has a route back to the person who treated them. A patient who flew for the procedure often does not, and this is a structural risk rather than a biological one. The stem cell tourism review notes that patients place themselves at risk both of receiving an unproven treatment and of travel-related illness, and that pre-travel health advice is largely absent from the clinics’ own materials[1]. A domestic clinician asked to manage a complication needs to know what was administered. “Exosomes” is not an answer to that question, as [the exosome page](https://stemcell-seoul.com/stem-cells-vs-exosomes/) sets out, isolation methods and source material vary between suppliers, and reviews identify that variability as an unresolved problem in the field[6]. Before travelling, get in writing what the material is, where it came from, and what was done to it. Recovery times and flight timing for common skin procedures are listed in [Delight Dermatology’s recovery-and-flight planner](https://hifuseoul.com/guides/downtime-planning-seoul/). ### Where the pressure comes from It helps to understand why the marketing is as confident as it is. A bioethics analysis of stem cell marketing in South Korea and the United States describes an industry that has offered cell-based interventions in the absence of conclusive evidence of safety and efficacy for over a decade, sustained by a combination of funding initiatives, permissive legal structures and belief systems that lent the practice legitimacy[7]. That is the environment in which a patient is being asked to make a judgement, and it is a reason to want documents rather than reassurance. When the reassurance is an “FDA-registered” label, [read what an FDA registration does and does not show](https://stemcell-seoul.com/fda-registered-vs-approved-records/). ### Contraindications and disclosure Before an elective injection, disclose infections, bleeding disorders, anticoagulant or antiplatelet use, pregnancy or breastfeeding, autoimmune conditions, abnormal scarring and allergies. Contraindications and precautions depend on the product and procedure. Autologous preparations also involve risks from collection. Bring your medication list, diagnoses, allergy history and scarring history to the consultation. ### References 1. Lyons S, Salgaonkar S, Flaherty GT. International stem cell tourism: a critical literature review and evidence-based recommendations. *Int Health.* 2022;14(2):132-141. [doi:10.1093/inthealth/ihab050](https://doi.org/10.1093/inthealth/ihab050) · [PMID:34415026](https://pubmed.ncbi.nlm.nih.gov/34415026/) 2. Julian K, Yuhasz N, Hollingsworth E, Imitola J. The "Growing" Reality of the Neurological Complications of Global "Stem Cell Tourism". *Semin Neurol.* 2018;38(2):176-181. [doi:10.1055/s-0038-1649338](https://doi.org/10.1055/s-0038-1649338) · [PMID:29791943](https://pubmed.ncbi.nlm.nih.gov/29791943/) 3. Ikonomou L, Weiss DJ. Turning the Tide on Unproven Cell-Based Interventions. *Chest.* 2020;157(4):774-775. [doi:10.1016/j.chest.2019.10.035](https://doi.org/10.1016/j.chest.2019.10.035) · [PMID:32252930](https://pubmed.ncbi.nlm.nih.gov/32252930/) 4. Cruciani M, Masiello F, Pati I, Marano G, Pupella S, De Angelis V. Platelet-rich plasma for the treatment of alopecia: a systematic review and meta-analysis. *Blood Transfus.* 2023;21(1):24-36. [doi:10.2450/2021.0216-21](https://doi.org/10.2450/2021.0216-21) · [PMID:34967722](https://pubmed.ncbi.nlm.nih.gov/34967722/) 5. Lampridou S, Bassett S, Cavallini M, Christopoulos G. The Effectiveness of Polynucleotides in Esthetic Medicine: A Systematic Review. *J Cosmet Dermatol.* 2025;24(2):e16721. [doi:10.1111/jocd.16721](https://doi.org/10.1111/jocd.16721) · [PMID:39645667](https://pubmed.ncbi.nlm.nih.gov/39645667/) 6. Haykal D, Wyles S, Garibyan L, Cartier H, Gold M. Exosomes in Cosmetic Dermatology: A Review of Benefits and Challenges. *J Drugs Dermatol.* 2025;24(1):12-18. [doi:10.36849/JDD.8872](https://doi.org/10.36849/JDD.8872) · [PMID:39761139](https://pubmed.ncbi.nlm.nih.gov/39761139/) 7. Sipp D. Cell Churches and Stem Cell Marketing in South Korea and the United States. *Dev World Bioeth.* 2017;17(3):167-172. [doi:10.1111/dewb.12120](https://doi.org/10.1111/dewb.12120) · [PMID:27214044](https://pubmed.ncbi.nlm.nih.gov/27214044/) ## Stem cell therapy in South Korea in 2026: the records and the 2026–2030 plan Source: https://stemcell-seoul.com/south-korea-stem-cell-therapy-2026/ Updated: 2026-10-24 The treatment plan that Korea’s Ministry of Health and Welfare announced on 24 April 2026 as advanced regenerative medicine treatment No. 1 uses each patient’s own immune cells, not stem cells, for 15 people with a rare lymphoma. Stem cells appear in the 2026–2030 basic plan as government-led studies for knee osteoarthritis and intractable chronic pain, scheduled from July 2026 to March 2028. Figure: Bar charts of Korean regenerative medicine records: 57 clinical research plans on the ministry’s count to December 2025 and 1 treatment plan on the portal list as of September 2026, against a 2030 goal of 150 or more research and treatment plans; and 223 designated institutions in June 2026, 44 tertiary hospitals, 56 general hospitals, 39 hospitals and 84 clinics Plans on record against the 2030 goal, and designated institutions by type. ### Treatment No. 1: what the April 2026 record describes Korea’s advanced regenerative medicine statute has two routes for cell-based interventions: clinical research, and, since February 2025, treatment. On 24 April 2026 [the ministry announced](https://www.mohw.go.kr/board.es?mid=a10503010100&bid=0027&act=view&list_no=1490286) the first plan on the treatment route. It covers people with EBV-positive extranodal NK/T-cell lymphoma who are in complete remission after chemotherapy but at high risk of relapse. The plan uses T cells derived from each patient’s own body and directed at an Epstein–Barr virus antigen, scheduled as one intravenous dose a week for four weeks, four weeks off, then four more weekly doses: eight in all over 12 weeks. It covers 15 patients. The ministry places the plan in the medium-risk tier. At that tier a treatment plan can be filed only after clinical research with the same purpose and content has been completed; this plan rests on a phase 2 trial run from 2017 to 2025 with 48 participants. [A 2026 analysis of the amended Act in Stem Cell Reports](https://pubmed.ncbi.nlm.nih.gov/41825446/) sets out the rest of the design: patients pay for treatment, while clinical research carries cost prohibitions, and the risk tier decides whether completed research must come first. The Act defines the people the treatment route is for: those with a serious disease for which there is no alternative treatment or which threatens life, a rare disease under the Rare Disease Control Act, or another intractable disease (Article 2(6)). ### The 2026–2030 basic plan in figures On 21 July 2026 the government’s policy committee adopted the [second basic plan for advanced regenerative medicine and advanced biological products](https://www.mohw.go.kr/board.es?mid=a10503010100&bid=0027&act=view&list_no=1491366), which the Act requires every five years (Article 5). The figures it reports: - 57 clinical research plans on the ministry’s count to December 2025; - 223 designated institutions in June 2026: 44 tertiary hospitals, 56 general hospitals, 39 hospitals and 84 clinics, according to [the June designation release](https://www.mohw.go.kr/board.es?mid=a10503010100&bid=0027&act=view&list_no=1490959); - a goal of 150 or more research and treatment plans in total by 2030. The plan also adds duties for designated institutions: a research or treatment plan within one year of designation, with grounds to cancel the designation of those that file none, and renewal every three years. The ministry said the amendment to the Act for these duties would be pursued in the second half of 2026, with advertising guidelines for regenerative medicine due in March 2027. It also set October 2026 for a notice moving cultured autologous immune cells from medium to low risk; at low risk, a treatment plan can be filed without prior clinical research. Figure: Timeline of Korean regenerative medicine records from February 2025 to 2030, separating recorded events from dates scheduled in the 2026–2030 plan Recorded events through July 2026, then the dates the plan sets. ### Where stem cells appear: four government-led studies The plan answers demand for treatment abroad with research at home first. It names four diseases with high demand for treatment abroad and schedules government-led multicentre studies for each. Figure: Table of four government-led studies: knee osteoarthritis and intractable chronic pain with the patient’s own cultured stem cells, blood cancer and recurrent glioblastoma with the patient’s own cultured immune cells Two of the four studies use stem cells; both are scheduled to March 2028. Two of the four use the patient’s own cultured stem cells: knee osteoarthritis and intractable chronic pain, both scheduled from July 2026 to March 2028. The blood cancer and recurrent glioblastoma studies use the patient’s own cultured immune cells. Each consortium plans for 60 to 165 participants over 21 months. According to the July release, the knee osteoarthritis, chronic pain and solid tumour (recurrent glioblastoma) studies were under way from July 2026, and the blood cancer study was due to be reviewed again that month with a revised protocol. The plan states that results will go to treatment-plan review, which weighs safety, efficacy and cost before treatment in Korea is decided. ### Advertising: what the 2025 monitoring found Between 7 July and 28 November 2025 the ministry checked blogs, YouTube, social media and websites for regenerative medicine advertising. On 28 May 2026 [it reported](https://www.mohw.go.kr/board.es?mid=a10503010100&bid=0027&act=view&list_no=1490640) 246 advertisements from 63 medical institutions to local governments for action. Of these, 236 (96%) came from 54 designated institutions, 36 of them clinics. Figure: Bar chart: 236 of 246 flagged advertisements came from designated institutions, 54 of 63 institutions were designated, and 36 of those 54 were clinics Most flagged advertisements came from designated institutions. The main pattern was an institution citing its designation while promoting a procedure unrelated to advanced regenerative medicine as if it were regenerative medicine of verified safety. The ministry’s example is a knee osteoarthritis injection, a new health technology, advertised as regenerative medicine. The same release lists two separate requirements: the institution’s designation, and the committee’s review of the specific research or treatment plan. The [advanced regenerative medicine portal](https://www.k-arm.go.kr/) publishes both. Which documents to ask a clinic for is set out in the [guide to Korean regenerative medicine law](https://stemcell-seoul.com/korea-regenerative-medicine-law/) and the [questions to ask a clinic](https://stemcell-seoul.com/questions-to-ask-a-clinic/). ### Research or treatment: what a visitor can plan around Read together, the 2026 records sort into three groups. On the treatment route, [the portal’s list of plans as of September 2026](https://www.k-arm.go.kr/brd/view.do?key=2102158637710&nttSn=900), posted on 6 October, has one entry: the April 2026 lymphoma plan. On the research route there are 57 plans counted to December 2025 and the government-led studies scheduled to March 2028. Advanced biological products, which the Act places under the Pharmaceutical Affairs Act, follow a separate product track. Whether a proposed intervention belongs to a research plan, a treatment plan or neither is the first point to settle before planning travel. Consultation logistics, from directions to what to put in a request, are covered in [a Seoul clinic’s planning notes for international patients](https://hifuseoul.com/for-international-patients/). The United States sorts the same question by federal product rules and state statutes: see [how US federal rules and state laws treat stem cell therapy](https://stemcell-seoul.com/is-stem-cell-therapy-legal-in-the-us/). ### Frequently asked questions ### Which stem cell studies does Korea’s 2026–2030 plan schedule? Government-led multicentre studies using the patient’s own cultured stem cells for knee osteoarthritis and intractable chronic pain, scheduled from July 2026 to March 2028, with 60 to 165 participants per consortium over 21 months. ### Where are Korean regenerative medicine records published? The ministry’s advanced regenerative medicine portal, k-arm.go.kr, lists designated institutions and the status of research and treatment plans. Ministry press releases report committee decisions with their dates. ### What did Korea’s 2025 check of regenerative medicine advertising find? Between 7 July and 28 November 2025 the ministry checked blogs, YouTube, social media and websites. On 28 May 2026 it reported 246 advertisements from 63 medical institutions to local governments for action; 236 came from 54 designated institutions. ### Primary sources 1. [Ministry of Health and Welfare: press reference release on advanced regenerative medicine treatment No. 1 (24 April 2026)](https://www.mohw.go.kr/board.es?mid=a10503010100&bid=0027&act=view&list_no=1490286). Disease, cell type, number of patients, risk tier and the prior phase 2 trial. 2. [Ministry of Health and Welfare: release on the second basic plan for advanced regenerative medicine and advanced biological products, 2026–2030 (21 July 2026)](https://www.mohw.go.kr/board.es?mid=a10503010100&bid=0027&act=view&list_no=1491366). Research count, designation duties, risk-tier notice, government-led studies and the 2030 goal. 3. [Second basic plan for advanced regenerative medicine and advanced biological products, 2026–2030 (draft, 21 July 2026), with the release, posted by the KDI Economic Information and Education Center](https://eiec.kdi.re.kr/policy/materialView.do?num=284540). Government-led study table, printed page 10. 4. [Ministry of Health and Welfare: results of 2025 online monitoring of regenerative medicine advertising (28 May 2026)](https://www.mohw.go.kr/board.es?mid=a10503010100&bid=0027&act=view&list_no=1490640). Monitoring period, counts by institution type and the portal for public records. 5. [Ministry of Health and Welfare: 2026 call for designation of advanced regenerative medicine institutions (22 June 2026)](https://www.mohw.go.kr/board.es?mid=a10503010100&bid=0027&act=view&list_no=1490959). Designated institutions by type, June 2026. 6. [Korean Act on the Safety of and Support for Advanced Regenerative Medicine and Advanced Biological Products](https://law.go.kr/LSW/lsInfoP.do?ancYnChk=0&chrClsCd=010202&efYd=20261008&lsiSeq=285347&urlMode=lsInfoP). National Law Information Center text, version [시행 2026. 10. 8.] [법률 제21525호, 2026. 4. 7., 타법개정]; Article 2 definitions, Article 3 and Article 5 basic plan. 7. [Advanced regenerative medicine portal (첨단재생의료포털)](https://www.k-arm.go.kr/). Designated institutions and research and treatment plan records. 8. [Advanced regenerative medicine portal: list of research and treatment plans as of September 2026 (posted 6 October 2026)](https://www.k-arm.go.kr/brd/view.do?key=2102158637710&nttSn=900). Treatment plan table. 9. Yoon J, Lee S, Kim JH. New legal category of ‘advanced regenerative medicine treatment’ in Korea’s amended regenerative medicine law: comparative lessons from Japan. Stem Cell Reports. 2026;21(4):102852. [PMID 41825446](https://pubmed.ncbi.nlm.nih.gov/41825446/) · [doi:10.1016/j.stemcr.2026.102852](https://doi.org/10.1016/j.stemcr.2026.102852). Treatment route, payment and risk tiers. Related guides: [how Korean law regulates regenerative medicine](https://stemcell-seoul.com/korea-regenerative-medicine-law/), [reading a clinical trial registration](https://stemcell-seoul.com/clinical-trial-registration-vs-approval/) and [safety and risks](https://stemcell-seoul.com/safety-and-risks/). A dermatology consultation starts from your own skin and medical history. ## Stem cells versus exosomes — the difference that matters Source: https://stemcell-seoul.com/stem-cells-vs-exosomes/ Updated: 2026-10-18 A stem cell is a living cell that can divide and differentiate. An exosome is a nanoscale vesicle (roughly 30 to 150 nanometres) that a cell releases, carrying proteins, lipids and nucleic acids. Exosomes are produced by cells but are not cells: exosomes do not self-replicate or engraft as living cells; their tissue residence and clearance depend on the preparation and delivery route. That difference determines the mechanism (signalling rather than replacement), the regulatory route, and the evidence base. Clinic pages that use the two words interchangeably are describing two different things. Figure: A large blue cell beside a magnifying glass surrounding a small red vesicle Figure: Typical reported size ranges for exosomes and mesenchymal stromal cells, shown on a logarithmic scale. Exosome about 30–150 nm Mesenchymal stromal cell about 15–30 µm Exosomes are vesicles; mesenchymal stromal cells are living cells. ### In short - Exosomes are cell products, not cells. They cannot divide independently like living cells. - The proposed mechanism for exosomes is paracrine signalling (delivering a cargo that changes what recipient cells do), not tissue replacement. - Exosome preparations and live-cell interventions can follow different regulatory pathways. The exact product and use determine the applicable requirements. - No exosome product holds US FDA approval for any indication. - "Exosome" on two labels need not describe the same material: isolation and characterisation methods vary between suppliers, which is why the research community publishes minimum reporting standards. ### What each one is #### Stem cells In aesthetic and reconstructive practice the cells in question are usually mesenchymal stem or stromal cells (MSCs), often obtained from adipose tissue. They are living, nucleated cells capable of division. Interest in them for tissue repair rests on a substantial body of laboratory and animal work demonstrating immunomodulatory, anti-inflammatory and wound-healing effects[2]. The clinical translation has been slower than the laboratory work. In aesthetic surgery the most developed application is cell-assisted lipotransfer (enriching a fat graft with stromal vascular fraction or adipose-derived cells to improve how much of it survives), and a systematic review of that approach describes it as a promising concept still facing unresolved problems in standardisation and manufacturing compliance[7]. #### Exosomes Exosomes are among the smallest extracellular vesicles, typically described in the 30–150 nanometre range, secreted by most cell types and carrying protein, lipid and nucleic acid cargo that can alter the behaviour of recipient cells[3]. The aesthetic interest is straightforward: if a stem cell’s useful effects are largely paracrine (that is, mediated by what it secretes rather than by what it becomes), then collecting the secretions may capture the benefit without administering a living cell. That reasoning is sound enough to justify research, and the mechanistic findings are real. Stem cell-derived exosomes have been shown to reduce matrix metalloproteinase expression and increase collagen and elastin production in models of photoageing[5], and reviews of dermatological application describe roles across wound repair, ageing and pigmentation[6]. What the reasoning does not do is transfer a stem cell’s evidence base to an exosome product. They are separate claims requiring separate testing. Small controlled studies and systematic reviews of exosome-containing preparations remain limited by product differences and combined procedures[8, 9]. ### Side by side Table: Comparison of stem cells and exosomes across eight properties | Property | Stem cells (MSC / ADSC) | Exosomes | | --- | --- | --- | | Is it alive? | Yes: living nucleated cells | No: vesicles released by cells | | Typical size | Roughly 15–30 micrometres | Roughly 30–150 nanometres | | Proposed mechanism | Differentiation, engraftment, and paracrine signalling | Paracrine signalling only: cargo delivery to recipient cells | | Can it divide or engraft? | Living cells can divide and may engraft, depending on the intervention | No independent division or engraftment as living cells | | How long does it remain in tissue? | Depends on the cells and intervention | Vesicle and cargo residence depend on the preparation and delivery route | | Source in aesthetic use | Usually the patient’s own adipose tissue | Usually cultured cells, so the material is not the patient’s own | | US FDA approval for aesthetic indications | None for cosmetic use | None: no exosome product is approved for any indication | | Strongest study design in aesthetics | Systematic review of cell-assisted fat grafting | Small controlled trials and systematic reviews; products, combined procedures and outcomes vary | ### The word “exosome” is doing unreliable work Primary source [MISEV: Minimal Information for Studies of Extracellular Vesicles](https://www.isev.org/misev): International Society for Extracellular Vesicles (ISEV) Scope of this source: A scientific reporting standard for research, now in its third edition. It defines how EVs should be characterised and described. It does not evaluate, certify or authorise any commercial product. There is a practical problem beneath the science. Isolating exosomes cleanly from other extracellular particles is technically demanding, and methods differ between laboratories and suppliers. The International Society for Extracellular Vesicles has now published three editions of its minimum information standards (MISEV2014, MISEV2018 and MISEV2023) precisely because nomenclature, separation from non-vesicular particles, and characterisation remained obstacles to comparing results across the field[1]. The consequence for a patient is direct. Two clinics offering “exosome treatment” may be administering materials that differ in source cell, isolation method, vesicle concentration and purity. Ask for documentation of the source cells, isolation method, vesicle concentration and purity. A 2025 comprehensive review of aesthetic exosome use identified exactly this, the absence of standardisation in production and application, as the limitation on drawing conclusions from the existing clinical reports[4]. Named booster products are compared by ingredient and evidence in [Delight Dermatology’s Juvelook, Rejuran and exosome comparison](https://hifuseoul.com/blog/juvelook-rejuran-exosome-skinbooster-comparison-seoul/). ### Checking product claims Three specific tells are worth watching for. A page that cites stem cell research to support an exosome product has skipped a step: the mechanism may be shared, the evidence is not. A page that says “FDA approved” anywhere near either word is making a claim that, for exosomes, corresponds to nothing: [the regulatory status page](https://stemcell-seoul.com/is-it-fda-approved/) covers what the FDA has actually published. And a page that will not tell you the source of the material (which cells, cultured how, isolated by what method) is withholding the information you would need to compare it to anything. The choice between these two categories is usually a false one. For most aesthetic and hair concerns the better-evidenced options sit outside the regenerative category altogether, and an examination is what establishes which problem is actually being solved. ### References 1. Welsh JA, Goberdhan DCI, O'Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. *J Extracell Vesicles.* 2024;13(2):e12404. [doi:10.1002/jev2.12404](https://doi.org/10.1002/jev2.12404) · [PMID:38326288](https://pubmed.ncbi.nlm.nih.gov/38326288/) 2. Ha DH, Kim HK, Lee J, et al. Mesenchymal Stem/Stromal Cell-Derived Exosomes for Immunomodulatory Therapeutics and Skin Regeneration. *Cells.* 2020;9(5):1157. [doi:10.3390/cells9051157](https://doi.org/10.3390/cells9051157) · [PMID:32392899](https://pubmed.ncbi.nlm.nih.gov/32392899/) 3. Haykal D, Wyles S, Garibyan L, Cartier H, Gold M. Exosomes in Cosmetic Dermatology: A Review of Benefits and Challenges. *J Drugs Dermatol.* 2025;24(1):12-18. [doi:10.36849/JDD.8872](https://doi.org/10.36849/JDD.8872) · [PMID:39761139](https://pubmed.ncbi.nlm.nih.gov/39761139/) 4. Shah M, Dukharan V, Broughton L, et al. Exosomes for Aesthetic Dermatology: A Comprehensive Literature Review and Update. *J Cosmet Dermatol.* 2025;24(1):e16766. [doi:10.1111/jocd.16766](https://doi.org/10.1111/jocd.16766) · [PMID:39764639](https://pubmed.ncbi.nlm.nih.gov/39764639/) 5. Hajialiasgary Najafabadi A, Soheilifar MH, Masoudi-Khoram N. Exosomes in skin photoaging: biological functions and therapeutic opportunity. *Cell Commun Signal.* 2024;22(1):32. [doi:10.1186/s12964-023-01451-3](https://doi.org/10.1186/s12964-023-01451-3) · [PMID:38217034](https://pubmed.ncbi.nlm.nih.gov/38217034/) 6. Xiong M, Zhang Q, Hu W, et al. The novel mechanisms and applications of exosomes in dermatology and cutaneous medical aesthetics. *Pharmacol Res.* 2021;166:105490. [doi:10.1016/j.phrs.2021.105490](https://doi.org/10.1016/j.phrs.2021.105490) · [PMID:33582246](https://pubmed.ncbi.nlm.nih.gov/33582246/) 7. Debuc B, Gendron N, Cras A, et al. Improving Autologous Fat Grafting in Regenerative Surgery through Stem Cell-Assisted Lipotransfer. *Stem Cell Rev Rep.* 2023;19(6):1726-1754. [doi:10.1007/s12015-023-10568-4](https://doi.org/10.1007/s12015-023-10568-4) · [PMID:37261667](https://pubmed.ncbi.nlm.nih.gov/37261667/) 8. Park GH, Kwon HH, Seok J, et al. Efficacy of combined treatment with human adipose tissue stem cell-derived exosome-containing solution and microneedling for facial skin aging: A 12-week prospective, randomized, split-face study. *J Cosmet Dermatol.* 2023;22(12):3418-3426. [doi:10.1111/jocd.15872](https://doi.org/10.1111/jocd.15872) · [PMID:37377400](https://pubmed.ncbi.nlm.nih.gov/37377400/) 9. Jafarzadeh A, Hoseini SS, Behrangi E, Roohaninasab M, Goodarzi A. Effectiveness of regenerative medicine for skin lightening and rejuvenation: a systematic review of extracellular vesicles and conditioned media. *Stem Cell Res Ther.* 2025;16(1):513. [doi:10.1186/s13287-025-04592-z](https://doi.org/10.1186/s13287-025-04592-z) · [PMID:41013717](https://pubmed.ncbi.nlm.nih.gov/41013717/) ## What regenerative medicine actually covers Source: https://stemcell-seoul.com/what-is-regenerative-medicine/ Updated: 2026-10-24 In aesthetic practice, “regenerative” describes four distinct families of product: living autologous cells; platelet-rich plasma, which contains platelets rather than stem cells; cell-free products such as conditioned media and exosomes; and polynucleotides including PDRN, which contain no cellular material at all. Their mechanisms, regulatory pathways and clinical evidence differ. Figure: A dropper bottle, blood tube, Petri dish and ampoule with different contents ### Why the category is misleading Regenerative medicine, as a research field, means using cells or cell-derived material to restore tissue structure or function. That is a legitimate and productive area of science. The difficulty is that the word travelled into aesthetic marketing intact, where it now attaches to any product a clinic wishes to describe as renewing rather than merely filling. The result is a category whose members have less in common than the label implies. Figure: Regenerative products differ in their contents. Product identity, processing and intended use determine the relevant regulatory pathway and clinical evidence. More cellular material None 1. Living nucleated cells - Autologous MSCs - Stromal vascular fraction - Adipose-derived cells 2. Anucleate fragments in plasma - Platelet-rich plasma (PRP) 3. Cell-derived preparations - Conditioned cell-culture medium - Exosomes and other extracellular vesicles 4. No cellular material - PDRN - Polynucleotides (PN) Ask what the product contains and what clinical studies show for that specific material and indication. Table: Four families of regenerative aesthetic product: contents, strongest published study design, and principal limitation. | Modality | What is actually administered | Strongest published evidence | Principal limitation | | --- | --- | --- | --- | | Autologous cells (MSC, SVF, ADSC) | Living nucleated cells harvested from the patient, processed to some degree, and returned. | Systematic review of cell-assisted lipotransfer, where cells are added to a fat graft rather than injected as a treatment in themselves. | Graft-retention rates in the underlying literature range from roughly 25% to 80%. Processing methods are not standardised between clinics. | | Platelet-rich plasma (PRP) | The patient’s own blood, centrifuged so platelets concentrate in a small plasma volume. Contains no stem cells. | Multiple systematic reviews and meta-analyses of randomised controlled trials, chiefly in androgenetic alopecia. | A 2023 systematic review graded the certainty of benefit as low, citing inconsistency and risk of bias. Preparation protocols vary between studies. | | Exosomes / extracellular vesicles | Nanoscale vesicles released by cells, carrying proteins, lipids and nucleic acids. Not living cells; preparation composition and purity require separate checks. | Small controlled trials and systematic reviews of extracellular vesicles and conditioned media; formulation and procedure differences limit generalisation. | No exosome product holds US FDA approval for any indication. Isolation and characterisation methods differ between suppliers, so "exosome" on two labels need not mean the same material. | | PDRN / polynucleotides (PN) | Purified DNA fragments, in the case of PDRN derived from salmon sperm DNA. No cells and no cell fragments. | A systematic review of nine studies in aesthetic use, plus a substantial pharmacology literature on PDRN in wound healing. | The included aesthetic studies were of low to moderate quality, with 219 patients in total and no consensus on optimal use. | ### Family one: living autologous cells This is what “stem cell treatment” literally means: mesenchymal stromal cells, stromal vascular fraction, or adipose-derived cells taken from the patient, processed, and administered back. Mesenchymal stromal cells attract research attention because they have immunomodulatory and regenerative functions demonstrated across a large body of laboratory and animal work[2]. In aesthetic and reconstructive surgery, the best-developed clinical application is not cells as a treatment in themselves but cells added to a fat graft to improve how much of the graft survives. A systematic review of this approach (cell-assisted lipotransfer, using PRP, stromal vascular fraction or adipose-derived stem cells as the enrichment) describes it as promising while noting that graft retention across the literature ranges from about a quarter to about four-fifths, and that transferring these techniques into standardised, good manufacturing practice-compliant production remains an open problem[9]. That gap between laboratory promise and reproducible clinical result is the honest state of the field. Regulatory classification depends on the cells, processing and intended use. [Korea’s framework for advanced regenerative medicine](https://stemcell-seoul.com/korea-regenerative-medicine-law/) requires institutional designation and plan review for interventions within its defined scope; specified minimally manipulated cell and tissue procedures are excluded. ### Family two: platelet-rich plasma Figure: After centrifugation, the buffy coat lies between plasma and red cells and contains leukocytes and platelets. 1. Plasma containing platelets The upper fraction; collection and further centrifugation depend on the system. 2. Buffy coat: leukocytes and platelets Collection of this layer varies with the preparation system. 3. Red cells The dense lower fraction, discarded. **The point:** PRP is plasma enriched with platelets. Platelet-containing plasma is collected and processed according to the preparation system; leukocyte content varies. PRP is plasma with a concentrated platelet fraction, prepared from the patient’s blood. Collection, further centrifugation and leukocyte content depend on the preparation system. Platelets are anucleate cell fragments that release growth factors on activation; they are not stem cells. PRP has randomised-trial evidence. There are randomised controlled trials in androgenetic alopecia and meta-analyses pooling them[6]. FDA-approved medicines include topical minoxidil and oral finasteride for their labelled populations; certain low-level light devices are FDA-cleared for specified pattern-hair-loss indications[10]. What the trials show, and what they fall short of showing, is set out on [the PRP and polynucleotides page](https://stemcell-seoul.com/prp-and-polynucleotides/). ### Family three: exosomes and conditioned media Cells in culture release substances into their surrounding medium. Collecting that liquid yields conditioned medium. Separating vesicles from it yields an extracellular-vesicle-containing preparation; identifying them specifically as exosomes requires evidence of endosomal origin. The mechanistic literature is genuinely interesting. Exosomes carry proteins, lipids and nucleic acids between cells, and stem cell-derived exosomes have been shown in laboratory and animal models to reduce matrix metalloproteinase expression and increase collagen and elastin production[3]. Reviews of dermatological applications describe plausible roles across wound healing, ageing and pigmentation[4]. Two facts should accompany all of that. First, no exosome product holds US FDA approval for any indication, and reviews of cosmetic use identify inconsistent isolation methods, source variability and the absence of long-term safety and efficacy trials as unresolved[5]. Second, the field has struggled to agree on what an exosome even is for measurement purposes: the International Society for Extracellular Vesicles has issued three successive editions of minimum reporting standards, most recently MISEV2023, specifically to address nomenclature, separation from non-vesicular particles, and characterisation[1]. If laboratories need a standard to agree on the terms, two clinic price lists using the same word are not necessarily describing the same material. ### Family four: polynucleotides and PDRN PDRN is a mixture of deoxyribonucleotides of defined molecular weight range, produced from salmon DNA through a controlled purification and sterilisation process designed to remove protein and peptide content. Its proposed mechanism is engagement of the adenosine A2A receptor together with supply of nucleosides for the salvage pathway[7]. It contains no cells and no cell fragments, which makes calling it “regenerative” a statement about proposed mechanism rather than about content. A 2025 systematic review of polynucleotides in aesthetic medicine found nine studies covering 219 patients, rated them low to moderate quality, and reported promising results on wrinkle depth, texture and elasticity alongside limited consensus on optimal use[8]. That is a fair description: some signal, small studies, no settled protocol. It is also worth noting that PDRN pharmacology should not be assumed to transfer wholesale to every product marketed as a polynucleotide: the source material, molecular weight distribution and manufacturing differ, and the mechanistic literature was built on PDRN specifically. One named polynucleotide product is described in [Rejuran product notes at Delight Dermatology](https://hifuseoul.com/procedures/rejuran-seoul/). Which of these four families, if any, is relevant to a particular concern depends on the diagnosis rather than the marketing. Pattern hair loss, photoageing and scarring are different problems with different evidence bases behind their respective treatments. ### Questions about a proposed product When a clinic, an advertisement or a search result says “regenerative,” the word has told you nothing yet. Ask which of the four families the product belongs to. Then ask what study design supports it for your specific indication: [the evidence levels page](https://stemcell-seoul.com/evidence-levels/) explains how to tell a meta-analysis from a case series and why the difference matters more here than in most of medicine. If the answer to either question is unclear, that is itself information. ### References 1. Welsh JA, Goberdhan DCI, O'Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. *J Extracell Vesicles.* 2024;13(2):e12404. [doi:10.1002/jev2.12404](https://doi.org/10.1002/jev2.12404) · [PMID:38326288](https://pubmed.ncbi.nlm.nih.gov/38326288/) 2. Ha DH, Kim HK, Lee J, et al. Mesenchymal Stem/Stromal Cell-Derived Exosomes for Immunomodulatory Therapeutics and Skin Regeneration. *Cells.* 2020;9(5):1157. [doi:10.3390/cells9051157](https://doi.org/10.3390/cells9051157) · [PMID:32392899](https://pubmed.ncbi.nlm.nih.gov/32392899/) 3. Hajialiasgary Najafabadi A, Soheilifar MH, Masoudi-Khoram N. Exosomes in skin photoaging: biological functions and therapeutic opportunity. *Cell Commun Signal.* 2024;22(1):32. [doi:10.1186/s12964-023-01451-3](https://doi.org/10.1186/s12964-023-01451-3) · [PMID:38217034](https://pubmed.ncbi.nlm.nih.gov/38217034/) 4. Xiong M, Zhang Q, Hu W, et al. The novel mechanisms and applications of exosomes in dermatology and cutaneous medical aesthetics. *Pharmacol Res.* 2021;166:105490. [doi:10.1016/j.phrs.2021.105490](https://doi.org/10.1016/j.phrs.2021.105490) · [PMID:33582246](https://pubmed.ncbi.nlm.nih.gov/33582246/) 5. Haykal D, Wyles S, Garibyan L, Cartier H, Gold M. Exosomes in Cosmetic Dermatology: A Review of Benefits and Challenges. *J Drugs Dermatol.* 2025;24(1):12-18. [doi:10.36849/JDD.8872](https://doi.org/10.36849/JDD.8872) · [PMID:39761139](https://pubmed.ncbi.nlm.nih.gov/39761139/) 6. Cruciani M, Masiello F, Pati I, Marano G, Pupella S, De Angelis V. Platelet-rich plasma for the treatment of alopecia: a systematic review and meta-analysis. *Blood Transfus.* 2023;21(1):24-36. [doi:10.2450/2021.0216-21](https://doi.org/10.2450/2021.0216-21) · [PMID:34967722](https://pubmed.ncbi.nlm.nih.gov/34967722/) 7. Squadrito F, Bitto A, Irrera N, et al. Pharmacological Activity and Clinical Use of PDRN. *Front Pharmacol.* 2017;8:224. [doi:10.3389/fphar.2017.00224](https://doi.org/10.3389/fphar.2017.00224) · [PMID:28491036](https://pubmed.ncbi.nlm.nih.gov/28491036/) 8. Lampridou S, Bassett S, Cavallini M, Christopoulos G. The Effectiveness of Polynucleotides in Esthetic Medicine: A Systematic Review. *J Cosmet Dermatol.* 2025;24(2):e16721. [doi:10.1111/jocd.16721](https://doi.org/10.1111/jocd.16721) · [PMID:39645667](https://pubmed.ncbi.nlm.nih.gov/39645667/) 9. Debuc B, Gendron N, Cras A, et al. Improving Autologous Fat Grafting in Regenerative Surgery through Stem Cell-Assisted Lipotransfer. *Stem Cell Rev Rep.* 2023;19(6):1726-1754. [doi:10.1007/s12015-023-10568-4](https://doi.org/10.1007/s12015-023-10568-4) · [PMID:37261667](https://pubmed.ncbi.nlm.nih.gov/37261667/) 10. Nestor MS, Ablon G, Gade A, Han H, Fischer DL. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. *J Cosmet Dermatol.* 2021;20(12):3759-3781. [doi:10.1111/jocd.14537](https://doi.org/10.1111/jocd.14537) · [PMID:34741573](https://pubmed.ncbi.nlm.nih.gov/34741573/) 11. Park GH, Kwon HH, Seok J, et al. Efficacy of combined treatment with human adipose tissue stem cell-derived exosome-containing solution and microneedling for facial skin aging: A 12-week prospective, randomized, split-face study. *J Cosmet Dermatol.* 2023;22(12):3418-3426. [doi:10.1111/jocd.15872](https://doi.org/10.1111/jocd.15872) · [PMID:37377400](https://pubmed.ncbi.nlm.nih.gov/37377400/) 12. Jafarzadeh A, Hoseini SS, Behrangi E, Roohaninasab M, Goodarzi A. Effectiveness of regenerative medicine for skin lightening and rejuvenation: a systematic review of extracellular vesicles and conditioned media. *Stem Cell Res Ther.* 2025;16(1):513. [doi:10.1186/s13287-025-04592-z](https://doi.org/10.1186/s13287-025-04592-z) · [PMID:41013717](https://pubmed.ncbi.nlm.nih.gov/41013717/)